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Objectives of the thesis 
 
The active pharmaceutical ingredients of biopharmaceuticals, therapeutic proteins, are 
heterogeneous mixtures containing many protein variants. The variants encompass protein 
modifications (e.g. oxidation or deamidation) and post-translational modifications (e.g. 
glycosylation or phosphorylation). These variants can have an influence on the structure and 
function of the therapeutic protein. The introduction (Chapter 1) reviews modifications of 
therapeutic proteins and gives an overview of published methods, studies and analytical 
technologies. Main focus is on N-glycosylation, a complex post-translational modification with 
potential influence on the pharmacokinetics. As described in the introduction the impact of N-
glycosylation on the pharmacokinetics of biopharmaceuticals is not yet fully understood. 
Studies investigating the criticality of N-glycans performed with different analytical 
approaches for different types of biopharmaceuticals resulted in part in contradictory 
conclusions. Consequently, a case by case evaluation has to be done for each type of 
biopharmaceutical. The aim of this thesis was to contribute to a better understanding of the 
structure-function relationship of N-glycosylation and pharmacokinetics of monoclonal 
antibodies and fusion proteins. The model proteins studied in this work were an Fc N-
glycosated but not Fab–glycosylated IgG1 and an Fc fusion protein with multiple N-
glycosylation sites. Central goal was to establish new highly sensitive, selective and robust 
analytical methods encompassing an affinity purification and LC-MS. The developed 
methodologies were to be implemented in the existing preclinical and clinical development. 
The major objectives were: 
 Development of an on-line LC-MS method based on RP chromatography for N-glycan 
analytics. (Chapter 2) 
 Development of high sensitivity N-glycosylation analysis of biopharmaceuticals by 
nanoLC-MS with high-throughput sample preparation. (Chapter 3) 
 Development and qualification of a high sensitivity affinity purification methodology for 
the isolation of monoclonal antibodies from complex matrices (serum). (Chapter 4) 
Use of the developed methods to investigate the 
 Influence of glyco-variants on the pharmacokinetics of an IgG1 biopharmaceutical. 
(Chapter 5) 
and the 
 Influence of glyco-variants on the pharmacokinetics of a therapeutic Fc fusion protein. 
(Chapter 6) 
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Chapter 1 
 
Introduction:  
N-glycosylation heterogeneity and the influence on 
structure, function and pharmacokinetics of 
monoclonal antibodies and Fc fusion proteins 
 
This chapter is intended for publication. 
 
Abstract 
Monoclonal antibody drugs are complex and heterogenic protein mixtures with many different 
variants and modifications. These alterations can greatly influence the structure and function 
of biopharmaceuticals. N-glycosylation as one of the most complex post-translational 
modification influences the structural characteristics of the antibodies Fc part thereby 
modulating the effector functions which potentially affects the pharmacokinetics. Several 
investigations on the relationship of N-glycosylation and pharmacokinetics have been 
published; however, this structure-function relationship is not yet fully understood. In this 
review potential alterations with focus on N-glycosylation of mAbs and Fc fusion proteins and 
the possible effects on the protein structure and function and finally on the pharmacokinetics 
are reviewed. The current understandings of the underlying mechanisms are described as 
well. 
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1.1. Introduction 
The fusion of murine myeloma cells with B-cells was a groundbreaking experiment of Köhler 
and Milstein and made production of antibodies in cell culture possible (1). It was the 
beginning of immunoassays and therapeutic antibodies. In 2012, more than 35 years later, 
34 recombinant monoclonal antibodies (mAbs) are marketed in the EU and US, mostly 
produced in CHO and SP2/0 cells (2). The vast majority of marketed mAbs belong to the IgG 
class or more precisely to the subclasses IgG1 and some IgG2 and IgG4. Two thirds of the 
marketed mAbs are either human or humanized and a small percentage is chimeric or 
murine (2). 
 
Figure 1: Schematic structure of an IgG molecule. An IgG consists of two heavy and two light chains that 
contain several domains. The variable domains VL (variable light) and VH (variable heavy) that form the 
antigen binding site and the constant domains CL (constant light) and CH1-3 (constant heavy) building 
the framework. The IgG can be furthermore divided into the Fab (fragment antigen binding) and Fc 
(fragment crystallizable) which induce the effector functions. On the right possible modifications and 
alterations of the IgG are listed. 
 
With more than 1300 amino acids resulting in a mass of approximately 150 kDa mAbs are 
large molecules built from two heavy chains with 50 kDa each and two light chains with 25 
kDa each (Figure 1). The different heavy chains (γ1, γ2, γ3 and γ4) divide the IgGs into their 
subclasses 1-4. The light chains are the κ-type and λ-type. Heavy and light chains are 
connected by disulfide bridges giving the antibody its Y-shaped structure (Figure 1). Intra-
chain disulfide bridges further stabilize the folding, 16 disulfide bridges per IgG1 and 7 per 
chain. The heavy and light chains consist of different domains. The variable domains VL 
(variable light) and VH (variable heavy) contain hypervariable regions that are responsible for 
antigen binding. The remaining domains are conserved sequences named the constant 
domains CL (constant light) and CH1-3 (constant heavy). The CH2 domain of each heavy 
chain contains one N-glycosylation site at approximately Asn297 and about one fifth of 
human IgGs carry a N-glycosylation motif in the variable region (3). The size and structure of 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
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IgGs give rise to a large number of possible alterations and modifications turning IgG drugs 
and in conclusion recombinant mAb drugs to heterogenic protein mixtures. 
The N-terminal amino acid residue, Glu or Gln, can undergo cyclization to pyroglutamate 
which results in mass reduction of 17 or 18 Da respectively and the loss of the positively 
charged N-terminal amine (4–7). Like the N-terminus, the C-terminus may be heterogenous 
because of different numbers of lysine residues at the heavy chain C-terminus, which in turn 
introduce additional positive charges (6). Deamidation of asparagine to aspartic acid or 
isoaspartic acid is another possible modification which increases the mass by 1 Da and 
introduces one additional negative charge to the protein (4, 6, 8). Deamidation of glutamine 
is possible too (9). Isomerization of aspartic acid to iso-aspartic acid or formation of iso-
aspartic acid as a result from deamidation introduces an additional CH2 group to the protein 
backbone, which can have tremendous effects on the mAb structure depending on the 
location of the modification (4, 6, 10, 11). Glycation, the non-enzymatic addition of a sugar to 
a primary amine (e.g. to a lysine side chain) of antibodies decreases the positive charge (6, 
12). Oxidation of methionine, tyrosine, tryptophan, histidine or cysteine increases the size by 
16 Da per oxidation reaction and increases the polarity of the respective residue (4, 6). 
Disulfide bond exchange and fragmentation of the IgG backbone, e.g. in the hinge region 
resulting in the loss of an entire antigen binding arm are also possible alterations of IgGs. All 
these alteration can have tremendous influence on the structure and function of monoclonal 
antibodies. The most complex post-translational modification of antibodies, N-glycosylation, 
is discussed in detail in the following. 
 
1.2. N-glycosylation and its influence on mAb structure and mAb effector 
function 
Like most extracellular glycoproteins, therapeutic proteins and specifically also mAbs 
undergo glycosylation in the ER and Golgi network of cells. The glycan structures of mAbs 
are important for the efficacy and safety of the drug (13). Consequently, glyco-engineering, 
controlled biosynthesis of only distinct glycan structures is of high interest and some 
sophisticated approaches have been described (14, 15). 
Monoclonal antibodies have one conserved N-linked glycosylation at the Fc part at position 
N297. Approximately 20% contain a second N-linked glycosylation site in their variable 
region. Both sites are located on the heavy chain (3, 13). Glycosylation of biopharmaceuticals 
shows a high grade of heterogeneity and N-glycans belong to the most complex and diverse 
structures in nature due to the high number of different sugar moieties and the multitude of 
possible linkages. Figure 2 shows the three different N-glycan types high mannose, complex 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
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and hybrid that are found on IgGs with their respective linkage. Complex and hybrid type 
exist with core fucosylation, addition of a fucose residue to the innermost N-
acetylglucosamine, and without core fucosylation. 
 
Figure 2: Types of N-glycans. The three different types (High Mannose, Complex and Hybrid) share a 
common core structure including the first two N-acetylglucosamine residues and the first three mannose 
residues. 
 
mAbs represent a special group of glycoproteins as their N-glycans are of limited size. This 
circumstance can be explained by the buried glycosylation site in the CH2 domain at 
Asn297, mAbs are usually free of N-glycans with more than two antennae and furthermore 
the sialic acid content is low compared with other glycoproteins (16). Typically, antibodies 
contain a high percentage of complex bi-antennary glycans with core-fucosylation (16–18). 
N-glycans have important structural functions. They stabilize the CH2 domain of IgGs and 
deglycosylation makes mAbs thermally less stable and more susceptible to chaotrope 
induced unfolding. In addition deglycosylated mAbs are more prone for aggregation (19). 
Beside the thermal and the colloidal stability, also the functionality of the IgG is influenced by 
the attached N-glycans and their size (20). In addition to the stabilization of the CH2 domain 
the attached N-glycans greatly influence the folding of the Fc part. Krapp et al. investigated 
crystalized Fc parts of IgG molecules with different homogenous glycosylations and could 
demonstrate that the conformation of the CH2 domain depends on the attached N-glycans 
(21). Larger N-glycans, e.g. bi-antennary complex type with terminal galactosylation, open up 
the Fc part in the CH2 region to a horseshoe like structure whereas smaller attached N-
glycans like the core structure favors a more “closed” Fc conformation. This open and closed 
formation can greatly influence the effector functions induced by interactions of the Fc part 
with Fc receptor molecules. The fact that crystallization of deglycosylated IgG was not 
possible due to the high flexibility of the CH2 domain shows the importance of N-glycan 
protein interactions (21). Hydrogen/Deuterium exchange MS experiments resulted in similar 
findings. Houde et al. showed that terminal galactosylation has major impact on the 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
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conformation of the Fc part and that fucosylation alone does not impact the conformation 
(22). NMR analysis of G2F glycosylated mAbs revealed that the terminal galactose residues 
are exposed and accessible for protein binding and that there are differences between the 
1,3 and the 1,6 arm concerning flexibility and accessibility (23). These findings led to the 
assumption that Fc N-glycosylation influences the effector function of proteins interacting 
with the CH2 domain. Upon antigen binding mAbs are able to induce effector functions 
mediated by their Fc-part. By binding to Fc-receptors or complement proteins mAbs induce 
ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement dependent 
cytotoxicity), respectively. ADCC is induced after binding of Fc-γ receptors (FcγR) to the Fc 
part (24). The affinity of FcγRs to the Fc part is influenced by N-glycosylation in the CH2 
domain (22, 25–28). As a consequence ADCC is enhanced for IgGs with lower fucosylation 
(25, 29). Binding affinity of the complement protein C1q to the IgG Fc which is involved in 
CDC is also influenced by N-glycosylation. and an increasing content of terminal galactose 
enhances CDC (29). By influencing CDC and ADCC, two important effector functions of 
therapeutic mAbs, N-glycosylation was thought to also have an impact on the 
pharmacokinetics of the glycosylated biopharmaceuticals. 
 
1.3. Pharmacokinetics of mAbs 
Monoclonal antibodies are large and complex structures with a different behavior in terms of 
their pharmacology and pharmacokinetics (PK) compared to low molecular weight drugs. 
Monoclonal antibodies show dose-dependent maximal concentrations typically in the range 
of µg/ml (nM range). mAbs typically exhibit a body half-life between 10 and 25 days, since 
they are not eliminated through kidney filtration due to their size and additionally escape fast 
degradation in the lysosomes through the neonatal Fc receptor (FcRn) recycling mechanism 
(30, 31). mAbs are usually administered by subcutaneous (sc), intramuscular (im) or 
intravenous (iv) injection. Whereas iv bioavailability is 100% per definition, for sc and im 
administration bioavailability values of 50 to 100% are reported (30). 
 
1.4. N-glycosylation and Pharmacokinetics 
Already in the 1970s, first evidence for the influence of sialic acids on the pharmakokinetics 
of glycoproteins was reported. Morell et al. observed that desialylated plasma proteins were 
cleared faster from circulation after injection into rats (32). There are two known major 
pathways for selective glycoprotein clearance. Glycoproteins in circulation with accessible 
terminal galactosylation are bound and cleared by the asialoglycoprotein receptor expressed 
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in the liver (33, 34). The second way of selective clearance of glycoproteins is through the 
mannose receptor (MR) which is most markedly expressed on immune cells (35–37). The 
mannose receptor binds selectively to mannose and N-Acetylglucosamine residues of N-
glycans (35, 36). Beside these pathways distinct mAb glycoforms may be faster cleared from 
circulation due to enhanced affinity to specific proteins rendering effector function (e.g. 
ADCC or CDC). The enzymatic conversion of glycans in vivo is the third option explaining the 
selective removal of distinct glycoforms. These possible pathways are pictured in Figure 1. 
 
Figure 3: N-glycosylation specific IgG interactions with a potential effect on the pharmacokinetics. (A) 
CDC activation through binding of C1q to the Fc part removes mAb from circulation. (B) ADCC is 
activated by binding of FcγR to the Fc part which is influenced by glycosylation. (C) Asialoglycoprotein 
receptor and (D) Mannose receptor mediated clearance routes of glycoproteins from circulation. (E) 
Enzymatic conversion of the mAb N-glycans during circulation by glycosidases. 
 
There are two basic options to investigate the effect of different glyco-variants on protein 
pharmacokinetics. Either distinct glyco-variants are enriched and compared in several study 
groups or the relative composition of different glyco-variants is directly followed in one study 
group. Millward et al. studied a mAb enriched to a high mannose portion at the Fc part of 
approximately 50% and a second mAb enriched for glycosylation in the Fab region. The PK 
profiles of the different mAb preparations were compared in mice by ELISA and the glycan 
pattern was analyzed at several time points by HPLC. No significant differences in PK 
properties were found (38). A second investigation in mice which compared PK parameters 
of degalactosylated IgGs with non-modified IgG came to the conclusion that 
degalactosylated IgG with terminal GlcNAc has a significantly longer half-life (39). Production 
and characterization of three differently glycosylated mAb qualities (Hybrid (+/- F), Complex 
(+/- F) and high mannose) against CD20 with bioassays (CDC, ADCC) and an in vivo study 
in mice demonstrated that the complex glycosylated mAb has a longer half-life, which is 
independent from fucosylation. Hybrid glycosylated mAb has a slightly shorter half-life and 
high mannose glycosylated mAb showed a strong decrease in half-life (40). Summarizing, 
the results from mice glycan PK profiling render an unclear picture with two studies reaching 
contradictory conclusions concerning the influence of high mannose structures on mAb PK in 
mice (38, 40). 
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Analysis of affinity purified mAb (IgG2) from clinical samples of two healthy human test 
subjects showed that the relative contribution of high mannose species M6-M9 to the total 
mAb plasma concentration decreased over time whereas M5 levels increased about the 
same percentage. It was hypothesized that the reduction of the IgG2 high mannose glycan 
blood levels is due to glycosidase activity in serum converting M6-M9 into M5 and not due to 
faster clearance. This hypothesis was supported with results from an in vitro assay. 
Incubation of the IgG2 in serum led to the same high mannose conversion as observed in the 
case study (41). The same group later published a second glycan PK profiling by mass 
spectrometry approach based on glycopeptide analysis by MS (42). Analysis of samples 
from four human subjects after administration of either one IgG1 or one of three IgG2 
molecules resulted in the finding that high mannose N-glycan M5 is selectively cleared from 
serum (Figure 4) (42). The authors furthermore showed that the IgG1 M5:M5 glycoform, the 
pairing of two M5 glycosylated heavy chains during protein biosynthesis is favored. A similar 
investigation of an IgG1 biopharmaceutical in humans confirmed the previously published 
(41) conversion of high mannose glycans in vitro. The results of the clinical study including 
15 healthy volunteers published in combination with the in vitro study showed that M5 had an 
increased serum clearance whereas M6 and M7 decreased in the first 6 h after 
administration followed by decreasing M5 levels and constant M6 and M7 (43). 
The production of mAbs with one distinct N-glycan and administration to mice demonstrated 
that a mAb with only M5 or M8/9 has an increased clearance and a shorter half-life. 
Furthermore, it was highlighted that the glycan pattern of the mAb with M8/9 changed over 
time to a high percentage of M6. This observation could be reproduced in vitro by incubation 
of the mAb in mice serum (44). The conversion of high mannose glycans to M6 instead of M5 
reported for mice implies a different underlying mechanism. A mouse study comparing yeast 
N-glycosylation (yeast specific high mannose type) and human glycosylation (complex type) 
revealed that antibodies carrying yeast glycosylation have shorter serum half-life than 
antibodies with human glycosylation (45). The influence of the glycosylation of the variable 
domain on antibody clearance was investigated by different groups (38, 46). As already 
mentioned Millward et al. did not find any influence of the variable domain N-glycosylation on 
the PK. In contrast Huang et al. came to the conclusion that molecules with bi-antennary 
glycans lacking galactosylation (terminal GlcNAc) attached in the variable domain are 
cleared slightly faster from circulation (46). 
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Figure 4: Reprinted from Goetze et al. with permission (42). The average percentages of IgG1 N297 
glycans from two subjects dosed with 1000 mg IgG1 intravenously are represented. Values represent the 
relative levels based on MS peak areas of all identified N297 glycopeptides. Error bars represent the 
range. Full-scale view shows several of the most abundant peptides (left); zoomed view showing 
representative lower abundance glycopeptides (right). 
 
Fc part containing fusion proteins are closely related to mAbs, because of the effector 
function induced by the Fc part of both biopharmaceuticals. Fc fusion proteins often carry 
several N-glycosylation sites in the non-IgG fusion protein part (47–49). There are a few 
reports on an influence of the terminal glycan residues of Fc fusion proteins on PK. Keck et 
al. compared Fc fusion protein batches with different N-glycosylation pattern, specifically 
terminal GlcNAc, galactosylation and sialylation (49). However, no site specific N-glycan 
analysis was performed which would enable to link effects to the Fc or the fusion protein part. 
The authors found that terminal GlcNAc is cleared faster. It was hypothesized that the 
mannose receptor might be responsible for the clearance as the 3D structure of the 
receptors demonstrated that the receptor can bind terminal GlcNAc containing glycans (49). 
In accordance with these findings Jones et al. represented that N-glycans with terminal 
GlcNAc residues have a higher clearance rate. Their protein of interest was the fusion 
protein lenercept containing a Fc part and two extracellular domains of a TNF-alpha receptor. 
Sialic acids and terminal galactosylation revealed only minor to no impact on the PK (48). 
Kogelberg et al. postulated a clearance mechanism for highly mannosylated proteins after 
studying an antibody Fc-enzyme fusion protein produced in the yeast P. Pastoris. They 
provided evidence for clearance of the glycoprotein by the mannose receptor, a glycan 
specific receptor which is expressed in sinusoidal endothelial cells in the liver (50). Reports 
from Liu et al. comparing differently glycosylated fusion proteins and mAbs produced in 
either glyco-engineered P. Pastoris or CHO cells highlighted that the sialic acid content of 
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fusion proteins modulates the pharmacokinetics (45, 51). Lower levels of sialic acids 
correlated with decreased serum half-life. 
 
1.5. Analysis of N-glycosylation in pharmacokinetic studies 
Immunoassays became the reference technique for PK-studies of therapeutic proteins, 
especially ELISA where the protein is captured by a specific antibody or in the case of 
therapeutic antibodies also by an anti-idiotypic antibody, an anti-species antibody or the 
appropriate antigen and finally detected by an enzyme-linked secondary antibody (52). 
However structural changes like deamidation, oxidation and especially the heterogeneity of 
glycoforms of the therapeutic protein, as discussed in previous sections, could alter the 
pharmacokinetic properties (53, 54) and immunoassay techniques are not able to detect 
such types of differences (52, 55). ELISA purely quantifies proteins and cannot distinguish 
between glyco-variants. Hence different analytical techniques are necessary. For the 
investigation of individual N-glycans LC and MS based approaches were mostly used in the 
previously described literature (38, 40–43, 46–48). Beside the analysis of intact glycoproteins 
which provides information about the most abundant glycoforms, the analysis of 
glycopeptides and released N-glycans is frequently used. Enzymatic release of N-glycans 
following labeling with a fluorophore like 2-AB or 2-AA and analysis by LC or LC-MS is 
perhaps the most widespread approach used in industry and academia (17, 18, 56–61). 
More sensitive approaches like nanoLC-MS, CE and CE-MS with LIF detection are also 
common and suitable for glycan related PK investigations (62–69). The advantage of these 
technologies for the glycan PK profiling is the possibility to analyze each N-glycan 
individually from a complex mixture which in turn leads to more accurate results compared to 
e.g. studies employing immunoassays after enrichment of specific glycoforms. 
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1.6. Conclusion 
Monoclonal antibody drugs are complex and heterogeneous protein mixtures. The N-
glycosylation on the antibody structure influences the function. Several investigations were 
published during the last decade trying to shed light on the relationship between N-
glycosylation and pharmacokinetics. In some studies distinct glycosylation fractions were 
enriched. However, with this approach a new artificial glycosylation pattern is generated that 
does not reflect the normal N-glycosylation of the biologic of interest and may render different 
outcome. The benefit of this approach is that simple standard analytics e.g. utilizing 
immunoassays can be performed to characterize the PK. Individual N-glycans analysis by 
MS based approaches can be used to analyze the heterogeneous biopharmaceutical 
directly. The major advantage of this MS approach is that the N-glycan levels can be 
analyzed in a relative manner. Individual N-glycans with influence on the PK can be identified 
rather simply. However, the MS approach requires high sensitivity. 
The studies investigating the relationship between N-glycosylation and pharmacokinetics led 
to in part contradictory findings. Overall, it is conclusive that high mannose glycans influence 
the PK of IgGs by increasing the clearance rate. For other N-glycans and glycoforms the 
results are less clear. Two studies investigating IgG variable domain glycosylation rendered 
inconsistent results and another study comparing differently glycosylated enriched fractions 
reported no difference. These inconsistent findings may be due to differences in study set-up 
(e.g. enrichment of distinct glycoforms), species (mouse, human), IgG subclass and IgG 
source (human, humanized, etc.). 
Results for the more complex glycosylated Fc fusion proteins with additional glycosylation 
sites in the fusion protein part also show an unclear picture for the effect of N-glycosylation 
on the pharmacokinetics. The N-glycans of the fusion proteins were mostly analyzed without 
site specificity. The N-glycans at the Fc part are buried between the heavy chains whereas 
the receptor part N-glycans could be more accessible for the interaction with specific 
enzymes or receptors. This phenomenon could result in different impact on the 
pharmacokinetics. 
Thus, over the last decade several investigations on the relationship between N-glycosylation 
of therapeutic proteins and pharmacokinetics were performed. With the use of sensitive 
technologies like LC-MS it became possible to change the analysis from comparing fractions 
of biopharmaceuticals enriched for specific N-glycans to the direct analysis of the complex 
glycosylated biopharmaceutical of interest. This results in more reproducible findings. With 
the rising number of biopharmaceuticals and biosimilars in development the need for N-
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glycan PK profiling and comparative studies will rise as well as the need for glyco-
engineering and optimization.  
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Abstract 
N-Glycosylation is a common post-translational modification of monoclonal antibodies with a 
potential effect on the efficacy and safety of the drugs; detailed knowledge about this 
glycosylation is therefore crucial. We have developed a reversed-phase liquid 
chromatographic–mass spectrometric method, with different fluorescent labels, for analysis 
of N-glycosylation, and compared the sensitivity and selectivity of the methods. Our work 
demonstrates that anthranilic acid as fluorescent label in combination with reversed-phase 
liquid chromatography–mass spectrometry is an advantageous method for identification and 
quantification of neutral and acidic N-glycans. Our results show that mass spectrometry-
based quantification correlates with quantification by fluorescence. Chromatographic 
discrimination between several structural glycan isomers was achieved. The sharp peaks of 
the eluting anthranilic acidlabeled N-glycans enabled on-line mass spectrometric analysis of 
even low-abundance glycan species. The method is broadly applicable to N-glycan analysis 
and is an orthogonal analytical method to the widely established hydrophilicinteraction liquid 
chromatography of 2-aminobenzamidelabeled N-glycans for characterization of N-glycans 
derived from biopharmaceuticals. 
 
 
 
 
 
Keywords: Anthranilic acid, 2-aminobenzamide, Mass spectrometry, N-glycosylation, 
Reversed-phase chromatography, Monoclonal antibody 
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2.1. Introduction 
Recombinant protein drugs are the most complex active pharmaceutical ingredients. 
Monoclonal antibodies (mAbs), glycoproteins with a molecular mass of approximately 
150kDa are one important class. Glycosylation has attracted interest because many 
investigations have shown that such modification may have an effect on the safety and 
efficacy of these therapeutic protein drugs (1–5). In general, IgGs have one conserved N-
glycosylation site on each heavy chain at their Fc part, usually at approximate position 297 of 
the heavy chain, and several mAbs carry a second N-glycosylation site in their variable 
region. The heterogeneity of the N-glycans attached to these sites is very high, far more than 
a dozen different glycans can be found (6). Identification and quantification of the glycans in 
this mixture is difficult, and Structural isomers of several glycans make discrimination even 
more difficult (7–9). A comprehensive analytical approach is therefore required. N-
glycosylation can be studied after enzymatic release of the glycans by use of peptide N-
glycosidase F (PNGaseF), by liquid chromatography, mass spectrometry (MS) (10) or by a 
combination of both technologies (9–14). Structural analysis of underivatized or labeled N-
glycans is usually performed by MALDI-MS or by use of porous graphitized carbon (PGC) 
liquid chromatography in combination with on-line ESI MS2 (15–17). 
Underivatized N-glycans have no light-absorbing properties. They can be derivatized with a 
fluorophore (18) for quantitative analysis by HPLC. Labeling with a fluorescent dye via 
reductive amination is widely used (12, 18). This derivatization results in high sensitivity and, 
because every N-glycan carries only one label, irrespective of size or branching, quantitative 
information can be obtained from the intensity of the fluorescence signal. The tag not only 
enables UV or fluorescence detection - it also improves ionization and fragmentation of the 
labeled N-glycan in ESI-MS (19, 20). 
For characterization of N-glycans derived from biopharmaceuticals  2-aminobenzamide (2-
AB) is routinely used as label (19, 21, 22), typically with separation and quantification by 
HILIC (Hydrophilic interaction liquid chromatography) with fluorescence detection (23). HILIC 
results in high resolution and selectivity for many glycan isomers (24). However the small 
injection volume of aqueous samples necessary, solvent conditions that are essential 
because of the solubility of the glycans, leads to reduced sensitivity in on-line MS detection 
and the buffered mobile phase may lead to ion suppression. 
In contrast with this, the mobile phases used for RP HPLC usually consist only of water, an 
organic solvent and an acid; they are, therefore highly MS compatible. In addition, there are 
almost no limitations with regard to injection volumes of aqueous solutions, which results in 
high sensitivity. It has been shown that RP LC-MS of 2-AB or ANTS derivatized 
oligosaccharides can be performed and used to characterize the N-glycosylation pattern of 
mAbs (13, 14, 25, 26).However, 2-AB as fluorescent tag adds only weak hydrophobicity to 
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the hydrophilic glycan which necessitates use of a shallow and long chromatography 
gradient. Furthermore, labeled acidic glycans elute early and are poorly separated (13). This 
limitationwas solved by Melmer et al. (24) by addition of an ion pairing reagent. However, use 
of an ion-pairing reagent again leads to ion suppression and thus reduced MS sensitivity. For 
analysis of negatively charged N-glycans containing sialic acids labeling with a negatively 
charged tag, for example 2-aminobenzoic acid (2-AA) or 8-aminonaphthalene-1,3,6-
trisulfonic acid(ANTS) and MS detection in negative ionization mode is frequently used (14, 
27–29). Prien et al. separated oligomannose structures (especially Mannose 5 isomers) by 
RP LC after 2-AA derivatization and analyzed them by use of MS in negative mode (28). The 
ability to separate complex N-glycan mixtures or isomers, for example the G1F N-glycans 
with either 1,3 or 1,6 galactosylation, highly abundant in most mAbs, has not been reported 
for any N-glycan RP-LC approach. 
 
To provide solutions for the above mentioned limitations of current N-glycan analytical 
methods we have developed and optimized an RP LC-MS method with positive ionization for 
characterization of complex N-glycosylation profiles. The method was designed to 
characterize acidic and neutral N-glycans in a single LC-MS approach. We compared the 
sensitivity and selectivity of 2-AB and 2-AA as fluorescent labels and showed that our newly 
developed 2-AA RP LC-MS method has advantageous sensitivity and selectivity for a variety 
of structural isomers analysis of which has not yet been reported in literature. By comparing 
results from quantitative MS and from FLD we also demonstrated that quantification of mAb 
glycans by these methods leads to very similar results. The method is versatile and can be 
used to address various questions in glycobiology or glycomics, from basic screening of N-
glycan composition, because of the grouping of the N-glycan types to detailed analysis of 
low-abundance glycan species. Furthermore our results show that even complex and highly 
sialylated N-glycans can be investigated. This flexibility and versatility make the method 
broadly applicable to analysis of N-glycans and it can be applied with little effort to analysis of 
many (glyco)protein or in proteomics and/ or glycomics laboratories, because the 
combination of RP LC and MS is a routine application in such laboratories.  
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2.2. Materials and Methods 
2.2.1. Materials 
PNGase F was from New England Biolabs (Frankfurt am Main, Germany). Acetonitrile (ACN) 
and acetic acid were from Merck (Darmstadt, Germany). Formic acid, DMSO and 
Sodiumcyanoborohydride was from Fluka (Sigma, Munich, Germany). Sephadex® G-10 
columns were custom made by GE Healthcare (Vienna, Austria). Amicon Ultra 30-K filter 
devices were from Millipore (Schwalbach, Germany). The mAb glycan standard was 
prepared at Sandoz. Monoclonal antibodies 1-3 were obtained from in-house development at 
Sandoz. The acidic N-glycan standards were from Thera Proteins (Barcarena, Portugal). 
 
2.2.2. Methods 
 
2.2.2.1. Enzymatic N-glycan release by use of PNGaseF 
Desalted mAb (1 mg) was used. The N-glycans (15 nmol) were released by incubating the 
samples with PNGaseF overnight (17 h) at 37°C. The N-glycans were separated from the 
proteins by use Amicon 30 K filter devices and were brought to dryness by use of a 
speedvac. 
 
2.2.2.2. Fluorescence labeling of released N-glycans or N-glycan standards 
Na[BH3(CN)] and either 2-AA or 2-AB were dissolved in 70:30 (% v/v) DMSO-acetic acid to 
furnish concentrations of 63 and 50 mg mL-1, respectively. Labeling solution (15 µL) and 
deionized water (10 µL) were added either to 15 nmol enzymatically released and dried 
glycans or to 250 pmol lyophilized N-glycan standard. The Labeling reaction was performed 
at 37°C for 17 h. 
Excess label was removed by gel filtration on G-10 columns. Columns were conditioned with 
10 ml H2O. Samples were diluted to 100 µl with deionized water then applied to the column. 
After rinsing the column with 700 µl H2O the purified fluorescence labeled N-glycans were 
eluted with 600 µl H2O. 
 
2.2.2.3. Reversed Phase HPLC of labeled N-Glycans 
Liquid chromatography was performed with an Agilent 1200 Series chromatograph on a 
Waters Acquity UPLC BEH130 C18 (2.1 mm x 150 mm 1.7-µm particle) column. Analysis of 2-
AA labeled glycans was performed with a gradient prepared from 1.0 % formic acid in H2O 
(component A) and 50 % ACN in 1.0 % formic acid in H2O (component B). The column was 
equilibrated with 4 % B. After injection of up to 100 µL sample the mobile phase composition 
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was held at 4 % B for 2 min. The proportion of B was then raised in four steps to 28%, first to 
10 % over 27 min, then to 11.5 % over 10 min, then to 14 % over 8 min and finally to 28 % 
over 19 min. The column was regenerated by increasing to 90 % B over 4 min, followed by 
isocratic elution for 2 min. The column was then re-equilibrated at 8 % B for 5 min. Oven 
temperature was 50 °C and the flow-rate was 0.30 mL min-1. Fluorescence detection was 
performed with an excitation wavelength of 250 nm and an emission wavelength of 425 nm. 
Analysis of 2-AB labeled glycans was performed with a gradient prepared from 0.5 % formic 
acid in H20 (component A) and 0.5 % formic acid and 5 % ACN in H20 (component B). The 
column was equilibrated with 25 % B. After injection the mobile phase was held at 25 % B for 
2 minutes, eluent B was increased to 55 % over 60 minutes and then increased to 61 % over 
24 minutes. The composition was held for 2 minutes and then initial condition was reached 
after 2 minutes and held for additional 5 minutes. Oven temperature was 40°C and the flow 
rate was 0.3 ml min-1 Fluorescence detection was performed with an excitation wavelength of 
250 nm and an emission wavelength of 428 nm 
 
2.2.2.4. Mass Spectrometry 
The HPLC was directly coupled to a 3D ion trap ESI-MS (Bruker AmaZon). The ion trap was 
operated in Enhanced Resolution Mode with a capillary potential of 4 kV. The capillary 
temperature was set to 250 °C with a nebulizer pressure of 2 bar and a dry gas flow of 6 
l/min. MS² spectra were generated by use of the Auto MS² mode and Collision Induced 
Dissociation (CID).  
 
  
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 2 
24 
 
2.3. Results and discussion 
2.3.1.  LC-MS of 2-AB labeled N-glycans 
Our RP LC-MS method entails use of two structurally closely similar chemical labels, 2-AB 
and 2-AA. In a first step an RP LC-MS method for 2-AB labeled N-Glycans was developed. 
Because 2-AB labeled N-glycans are weakly retained on C18 columns, a mobile phase 
gradient with a low organic solvent content was used. The separation was optimum under 
the mobile phase conditions decribed in the section “Reversed-phase HPLC of labeled N-
glycans. A fluorescence chromatogram obtained from the 2-AB RP-LC-MS method for the 
mAb glycan standard is shown in Figure 1. The glycans elute in groups. To reduce the run 
time the mobile phase composition was adapted. Use of formic acid instead of acetic acid 
improved retention and led to sharper peaks. A run time of 95 min was sufficient for analysis 
of the N-glycans of a mAb. A shorter gradient and the resulting reduction of run time led to 
loss of resolution, because of the low hydrophobicity of the labeled N-glycans. 
The first compounds eluting between 16-30 min from the column are the high-mannose 
glycans, in the order with high to low number of mannose residues (Figure 1, green). The 
acidic hybrid and complex glycans (Figure 1, pink) overlap with the oligomannose group from 
approximately 22-26 min. The next glycans to elute are the hybrid N-glycans lacking the core 
fucose at the terminal GlcNAc (Figure 1, orange), eluting from 28-36 min. The complex bi-
antennary 2-AB glycans elute in the middle of the chromatogram (Figure 1, blue, 42-48 min.) 
immediately before the acidic hybrid glycans with core fucose. Hybrid (Figure 1, orange, 57-
71 min.) and acidic complex (Figure 1, pink 48-66 min.) 2-AB glycans, both groups with a 
fucose residue attached to their core, co-elute. The group with the most abundant glycans in 
most mABs, the complex type glycans with core-fucose, elute at the end of the 
chromatogram with a retention time of 74-88 min. Sialic acid-containing 2-AB labeled glycans 
elute as sharp peaks before their corresponding neutral glycans.  
Labeled oligomannose and hybrid structures elute from high to low number of 
monosaccharides whereas complex type 2-AB glycans, including the acidic variants, elute 
from low to high number of monosaccharide units. Several 2-AB glycans elute with similar 
retention time and could not be separated. The 2-AB labeled glycans were identified by MS 
and MS2 by use of the ion-trap mass spectrometer. Table 1 contains the MS data for the 
identified glycans and the respective glycan structures are drawn in Figure 3 with the 
appropriate nomenclature.  
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Figure 1: Fluorescence chromatogram obtained from separation of 2-AB N-glycans on a RP column. The 
magnified view (B) of the chromatogram shows the smaller peaks of less abundant N-glycans. The 
numbered peaks were identified by use of MS and MS
2
. Stacked numbering indicates co-elution of N-
glycans. MS data of the identified peaks are listed in Table 1. The 2-AB glycans elute in different groups 
depending to their type. Oligomannose (green) glycans elute first, followed by acidic hybrid and complex 
type (pink) and neutral hybrid glycans (orange). Acidic hybrid with core fucose (pink) elute after complex 
glycans (blue). Neutral hybrid structures (orange) co-elute between approximately 57 and 86 min with 
acidic complexes followed by complex 2-AB glycans (blue), with all three groups carrying a core fucose. 
 
2.3.2.  Separation of 2-AA labeled N-glycans 
As an alternative to 2-AB labeled glycans 2-AA labeled glycans were also tested using the 
developed 2-AB method. Most 2-AA glycans remained on the column after the 95-min 
gradient, only the oligomannose structures eluted late. Because of this stronger retention of 
the 2-AA labeled glycans the mobile phase had to be adapted to enable optimum separation. 
In contrast with 2-AB, 2-AA is negatively charged at neutral pH. Mobile phase pH was 
therefore reduced to provide sufficient protons for efficient ionization in positive MS mode. 
Use of 1 % formic acid and an ACN content of component B increased by a factor of 10 
compared with the 2-AB method to 50 % enabled optimum separation and good ionization. 
Higher signal intensity was observed with positive-ionization MS compared with negative 
ionization mode. The resulting run-time was 78 min. As observed for the 2-AB method a 
shorter gradient resulted in substantial loss of resolution. 
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Figure 2: RP chromatogram obtained from the mAb glycan standard showing the grouping of the eluting 
2-AA N-glycans. (A) High Mannose structures elute first (green), followed by non-fucosylated hybrid 
(orange) and complex glycans (blue). Fucosylated hybrid (orange) and complex structures (blue) elute 
last in the chromatogram. Acidic glycans elute immediately before their appropriate neutral glycans 
(pink). (B) Magnified view of the region between 18 and 42 min showing the less abundant glycans. The 
identified glycans are numbered and the appropriate masses are listed in Table 1. Stacked numbering 
indicates co-elution of N-glycans. The glycan structures are depicted in Figure 3 
 
Figure 2 shows a fluorescence chromatogram obtained from the 2-AA labeled mAb glycan 
standard; it is similar that from of the 2-AB method (Figure 1). The labeled glycans elute in 
different groups, highlighted with different colors in Figure 2. High-mannose structures are 
the first group eluting from high number to small number of monosaccharide residues, for 
example from M9 to M5 (green, 19-27 min). Sialic acid containing non-fucosylated hybrid and 
complex variants (pink, 23-30 min) are then followed by the neutral non-fucosylated hybrid 
variants (orange, 28-31 min). Complex structures lacking the core fucose (blue, 30-34 min) 
elute before sialic acid containing hybrid glycoforms and sialic acid containing complex forms 
(pink, 34-40 min), both with core fucosylation. Bi-secting structures co-elute with the latter. 
Neutral core-fucosylated hybrid glycans (orange, 39-42 min) elute before the most abundant 
core fucosylated complex variants in mAbs, the bi-antennary N-glycans (blue, 42-51 min). 
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This grouping is similar to that of our 2-AB approach and to those of previous investigations 
(13). Sialic acid containing non-fucosylated hybrid and complex variants elute after the high 
mannose and before the neutral non-fucosylated hybrid group. The same order is observed 
for the core fucosylated hybrid and complex glycoforms. Again, the same sharp peak shape 
was obtained for the eluting sialic acid containing 2-AA glycans as for neutral glycans without 
the need for an ion-pairing reagent. Compared with the 2-AB method, the peaks were 
sharper (e.g. the peak width of peak 63 is 0.72 min. (2-AB) compared with 0.25 min (2-AA) 
and more condensed. Because of the greater number of separated glycan structures more 
partially resolved peaks are present in the chromatogram. 
 
2.3.3. Identification of N-glycans by use of positive mode ESI-MS and MS2 
So far, 2-AA has been used almost exclusively with negative ionization MS (27, 29), because 
of the negative charge of the acid group. The acidic mobile phase used in this investigation 
favors proton adducts and resulted in good ionization efficiency in positive ionization mode. 
We observed higher signal intensities for positive ionization than for negative ionization. The 
high formic acid content of the mobile phase also led to formation of formic acid clusters. 2-
AA N-glycans were identified from their mass derived from mass spectra and from the mass 
of appropriate fragments generated by CID. All identified 2-AB and 2-AA N-glycans identified 
in the mAb glycan standard, with their observed and calculated masses, are listed in Table 1. 
Some glycan structures occur several times in course of the chromatogram. These may be 
structural isomers or bisecting or tri-antennary variants with the same mass that cannot be 
distinguished because no linkage information is obtained by use of this LC-MS approach. 
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Table 1: 2-AA and 2-AB labeled glycans from mAb glycan standard identified by ion-trap MS and MS
2
. 
Observed and theoretical mass are shown for each assigned glycan.For N-glycan isomers only one mass 
is shown. The peak numbers correspond to the appropriate peak numbering in the chromatograms and to 
the structures in Figure 3. 
 2-AA Glycans 2-AB Glycans 
Peak Observed 
Mass 
Theoretical 
Mass 
Observed 
Mass 
Theoretical 
Mass 
N-Glycan 
5 1841.602 1841.645 1840.689 1840.661 M8 
6,7,8,9 1679.541 1679.592 1678.604 1678.608 M7 
10 1031.406 1031.381 1030.425 1030.397 M3 
11 1234.470 1234.460 1233.489 1233.476 M3G0 
12 2027.716 2027.709 2026.739 2026.725 SM5G1 
13,14 1517.592 1517.539 1516.573 1516.555 M6 
15 1396.550 1396.513 1395.54 1395.529 M3G1 
16 1855.655 1865.656 1865.678 1864.672 SM4G1 
17,18,19 1703.619 1703.603 1702.615 1702.619 SM3G1 
20,21 1193.457 1193.433 1192.49 1192.449 M4 
22 1355.525 1355.486 1354.533 1354.502 M5 
23,24 1558.617 1558.566 1557.582 1557.582 M5G0 
25 1720.647 1720.618 1719.643 1719.634 M5G1 
26,27,28,29 1599.618 1599.592 1598.612 1598.608 G1 
30 1720.647 1720.618 1719.643 1719.634 M6G0 
31 1558.592 1558.566 1557.576 1557.582 M4G1 
32,33 1437.586 1437.539 1436.565 1436.555 G0 
34 1687.579 1687.608 - 1686.624 SM3G1 
35,36 1786.675 1786.677 1785.708 1785.693 G0F+GN 
37 1583.710 1583.597 1582.648 1582.613 G0F 
38 2173.726 2173.767 2172.78 2172.783 SM5G1F 
39 2011.693 2011.714 2010.754 2010.73 SM4G1F 
40 2376.763 2376.846 2375.787 2375.862 SG3F 
41 1849.705 1849.661 1848.692 1848.677 SM3G1F 
42,43 2214.754 2214.793 2213.818 2213.809 SG2F 
44,45 2052.732 2052.740 2051.768 2051.756 SG1F 
46 1948.741 1948.729 1947.804 1947.745 G1F+NG 
47 2028.702 2028.729 - 2027.745 M6G1F 
48,49 1907.689 1907.703 1906.775 1906.719 G2F 
50 1866.679 1866.676 1865.698 1865.692 M5G1F 
51,52 1704.609 1704.624 1703.644 1703.64 M5G0F 
53 1866.650 1866.676 1865.668 1865.692 M6G0F 
54 1583.533 1583.597 1582.608 1582.613 M3G0F+N
G 55 1704.609 1704.624 1703.643 1703.64 M4G1F 
56,57 1542.566 1542.571 1541.582 1541.587 M3G1F 
58 2069.748 2069.756 - 2068.772 G3F 
59 1380.553 1380.518 1379.569 1379.534 M3G0F 
60 1907.690 1907.703 1906.746 1906.719 G2F 
61,62 1745.610 1745.650 1745.655 1744.666 G1F 
63 1583.709 1583.597 1582.607 1582.613 G0F 
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Figure 3: Symbol structures of the identified N-glycans. Numbering is in aqccordance with the peak 
numbering for the N-glycans in the fluorescence chromatograms and in Table 1. For structures with 
multiple peak assignments only one possible isomer is drawn. Symbols: L-Fucose,  N-Acetyl-D-
glucosamine,  D-Mannose,  D-Galactose,  N-Glycoyl-neuraminic acid,  N-Acetyl-neuraminic acid. 
 
The charge states of the labeled glycans increase with increasing mass. Glycans with a 
mass < 1200 Da occur almost exclusively as [M+H]1+ ions, whereas glycans with mass > 
1200 Da are doubly charged [M+2H]2+, singly charged [M+H]1+ ions, also are present for 
glycans of mass < 1500 Da. For mass ranges > 1800 Da, the N-glycans begin to ionize as 
triply charged [M+3H]3+ ions with the exception of oligomannose type glycans which usually 
furnish doubly charged ions. Adduct ions are present for all charge states and the 
oligomannose glycans tend to have the highest affinity for adduct formation. Doubly and triply 
charged ions occur as mixed adducts too. [M+Na]1+, [M+K]1+ , [M+H+Na]2+, [M+2Na]2+ and 
[M+H+K]2+ are the most abundant adduct ions. On-line MS detection provides more 
information than is required for identification N-glycans solely on the basis of their mass and 
fragments, because co-eluting 2-AA N-glycans can be identified and quantified by use of the 
extracted ion chromatograms (EICs) of the appropriate m/z values. 
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Figure 4: MS
2
 spectrum of the 2-AA labeled SG1F glycan from mAb3 at m/z 1027.9. The dissociated bonds 
of the [M+2H]
2+
 ion are depicted and the assigned B and Y ions are labeled in the spectrum. Dissociation 
of two bonds is indicated by a slash. 
 
 
Figure 4 and Figure 5 show the MS2 spectra obtained after fragmentation of different N-
glycoyl-neuraminic acid containing 2-AA glycans. The fragments were labeled in accordance 
with the nomenclature of Domon and Costello (30). The spectra were acquired on-line by use 
of positive ionization ESI-MS and CID fragmentation. Each of the SG1F 2-AA glycan 
fragments (Figure 4) can be explained by the dissociation of a single bond as expected from 
use of CID in ion-traps. The MS2 spectrum at m/z 1027.9 is dominated by B and Y ions. The 
fragmentation pattern of the sialic acid containing SM5G1F (Figure 5) is slightly different. In 
the MS2 spectrum of the [M+2H]2+ ion at m/z 1088.4 only B ions are observed derived from 
the GlcNAc containing branch, but not from the mannose containing branch of the hybrid 
structure. The fragments B3α and Y6α with m/z 528 and 366 respectively can be explained by 
loss of the terminal sialylation. 
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Figure 5: MS
2
 spectrum of the 2-AA labeled SM5G1F glycan from mAb3 at m/z 1088.4. Singly charged B 
and Y ions resulting from the [M+2H]
2+
 ion are shown. B ions were exclusively from the α-branch 
containing a GlcNAc that is able to carry a charge. Dissociation of two bonds is indicated by a slash. 
 
 
Figure 6 shows the MS² spectrum at m/z 1035.9 of the rare G3F glycan which accounts for 
less than 0.01% of the glycans. B ions are observed for both branches of the glycan because 
both contain a GlcNAc. This 2-AA glycan co-elutes with the two overlapping and more 
abundant M3G0F and G2F peaks, but it can be identified and quantified by use of on-line MS 
detection. To check the performance of the method for more complex sialic acid glycans we 
labeled and analyzed six acidic glycan standards (Figure 8 and also the section “Selectivity 
of the two approaches”). The bi-antennary glycans ionized as described above. For the tri 
and the tetra-antennary glycans we observed mainly [M+3H]3+ and [M+4H]4+ ions. Loss of 
terminal sialic acids was minimal and we observed almost no in-source fragmentation. Only 
loss of an antenna was monitored for the tetra-antennary N-glycan. 
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Figure 6: MS
2
 spectrum of the 2-AA labeled G3F N-glycan from mAb3. The dissociated bonds of the 
[M+2H]
2+
 ion are depicted and the assigned B and Y ions are labeled in the spectrum. The glycan 
accounts for <0.01 % of the glycans of mAb3. Dissociation of two bonds is indicated by a slash. 
 
 
2.3.4. Selectivity of the two approaches 
As mentioned in the “Introduction”, the complexity of glycosylation is not only because of the 
multitude of different N-glycan variants with different monosaccharide composition. It is also 
because of the existence of structural isomers with different linkage types. To obtain a 
glycan-map as comprehensive as possible it is important to separate these isomers. 
Separation of oligomannose isomers, for example, has been investigated and described in 
several publications (8, 13, 28). 
Figure 7 shows the EIC of the M7 isomers of mAb2 for the 2-AB (Figure 7a) and 2-AA 
(Figure 7b) labeled glycans. Four different isomers are observed for this high mannose 
glycan. The linkage could not be deduced with the reducing end derivatization used. The 
selectivity of the two methods is identical for the high-mannose structures; by comparison of 
the areas of peaks 3 and 4, however, we deduced that the order of elution might have 
changed because the ratio of the peak areas was inverted for the two labels (approx. 1.6 for 
2-AA peaks 3:4 and approx. 1.6 for 2-AB peaks 4:3).  
20
40
60
80
100
500 750 1000 1250 1500 1750 2000 2250 2500
m/z
366.062
528.180
1+
1381.592
1543.614
1705.643
B3α
Y4α
B2β
Y4β
Y3α
B3β
B3α or B3β
Y4β
Y4α
B2β
Y3α
- 2AA
In
te
n
s
it
y
 [
%
]
1178.522
Y4α/Y4β 1+
1+
+
1+
1+
954.849
2+
Y6α or Y5β
Y6α
Y5β
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 2 
33 
 
 
Figure 7: EICs of four structural M7 isomers (a;b) and G1F isomers (c;d) from mAb2. (a) EIC of 2-AB 
labeled N-glycans. (b) EIC for the 2-AA labeled glycans. Although selectivity is identical for the M7 
isomers in both approaches, comparison of the peak areas reveals the order of elution changed for peaks 
3 and 4. Selectivity is different for the G1F isomers. The 2-AB labeled G1F elutes as one peak (c), whereas 
the 2-AA labeled glycans (d) are separated into the two isomers. The terminal galactose residue (e) can be 
either linked to the α1,6 or the α1,3 branch of the bi-antennary N-glycan. 
 
G1F isomers are usually highly abundant structural isomers on mAbs and IgG (Figure 7e) 
with the terminal galactose residue at the α1,3 or α1,6 branch (6). So far separation of these 
two isomers has been achieved by use of HILIC and porous graphitized carbon liquid 
chromatography only (24). In Figure 7 it is clearly apparent that the combination of 2-AA as 
label and the RP chromatography conditions chosen is capable of separating these isomers 
whereas the 2-AB RP method is not. Figure 7c shows the EIC of the G1F 2-AB glycan which 
elutes as one peak because separation could not be achieved during method development. 
Figure 7d illustrates the selectivity of the 2-AA method toward the complex N-glycans. From 
quantitative data obtained by HILIC chromatography we could deduce that the first, larger 
peak is that of the α1,6 isomer and the second smaller peak is that of the α1,3 isomer. 
 
Figure 8: Overlay of fluorescence chromatograms derived from six different 2-AA labeled sialic N-glycan 
standards.The appropriate structures are depicted. The grouping into non-fucosylated (three peaks on 
the left) and fucosylated (three peaks on the right) glycans is obvious.  
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We also evaluated the performance of our 2-AA method with more highly branched N-
glycans with additional sialic acids. Six N-glycan standards with two, three and four antennae 
were labeled. Each glycoform is present with and without a core-fucose. All antennae carry 
one terminal N-acetyl sialic acid. Overlays of the chromatograms, with the appropriate glycan 
structure, are shown in Figure 8. The acidic N-glycans elute in accordance with the overall 
grouping (Figure 2) and the separation between fucosylated and non-fucosylated glycans is 
obvious.  
 
2.3.5. High sensitivity as a result of large injection volume 
The possibility of using large injection volumes of aqueous samples in RP LC enables 
detection and identification by fluorescence detection or mass spectrometry, of N-glycan 
variants which occur only at very low levels. Compared with HILIC in which only few 
microliters of an aqueous sample can be injected, this circumstance is of huge advantage 
because the labeled and purified N-glycans are eluted in 600 µl H2O in the last step of our 
sample preparation procedure. The sample can be injected without any additional 
concentration steps. N-glycans accounting for less than 0.01 % of total mAb N-glycans, for 
example G3F (shown in Figure 6) can be easily detected and identified by ion-trap MS 
resulting in a high sensitivity glycan map of the analyzed mAb. 
 
2.3.6. Analysis of different glycosylated mAbs 
We analyzed the glycosylation pattern of three different mAbs by use of the 2-AA RP LC-MS 
method to demonstrate the flexibility and versatility of the method for mAb N-glycan 
characterization. The fluorescence chromatograms are shown in Figure 9-11. These mAbs 
were chosen because of their different glycan content. The N-glycosylation pattern of mAb1 
(Figure 9) is indicative of the smallest amount of high-mannose structures but the largest 
amount of non-fucosylated complex glycans. Moreover it is the only mAb with both N-acetyl 
neuraminic acid and N-glycoyl neuraminic acid. It consists of 2 % high-mannose structures 
and <1 % hybrid structures without core fucose and 7 % are complex structures lacking the 
core fucose. Hybrid and complex N-glycans with α1,6 core fucose account for <1 % and 90 
% respectively. Approximately 2 % of the N-glycans carry a terminal sialic acid. 
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Figure 9: RP FLD chromatogram obtained from mAb1 N-glycans after labeling with 2-AA. Peaks identified 
by MS and MS
2
 are numbered and are listed in Table 1. The appropriate 2-AA glycans are shown in Figure 
3. The magnified view (small window) of the chromatogram shows the smaller peaks. 
 
 
mAb2 (Figure 10) has the highest amount of different oligomannose glycans and carries no 
sialylation. High-mannose structures account for 7 % of all glycans. Non-fucosylated hybrids 
account for <1 % and non-fucosylated complex types account for 2 % of the glycans. Hybrid 
and complex glycoforms with core fucose account for 1 % and 90% respectively. Relative 
amounts of glycans obtained from either fluorescence or MS results are listed, as examples, 
in Table 2. FLD data were obtained from integration of the peaks. Quantification by MS was 
performed by use of extracted ion chromatograms for the appropriate glycans. In general the 
comparison shows there is good correlation between FLD and MS results, demonstrating the 
accuracy of the methods. Co-eluting structures 50, 52, 59 and 60 could be quantified 
individually by MS. The differences between MS and FLD detection for peaks 62 and 63 can 
be explained by the overlapping of the two peaks. For FLD quantification the peaks were split 
resulting in a higher peak area for peak 62 whereas for MS detection the peaks could be 
quantified individually by use of their EICs. In the sum the peak areas are equal. There are 
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larger differences between the EIC and FLD values for some glycan species of minor 
abundance; these result from larger relative integration errors of the EIC and FLD signals. 
 
 
Figure 10: RP FLD chromatogram obtained from mAb2 N-glycans after labeling with 2-AA. Peaks 
identified by MS and MS
2
 are numbered and are listed in Table 1. The appropriate 2-AA glycans are shown 
in Figure 3. The magnified view (small window) of the chromatogram shows the smaller peaks. Stacked 
numbering indicates co-elution of N-glycans. Quantitative data obtained from FLD and MS for mAb2 are 
listed in Table 2. 
 
mAb3 (Figure 11) has the most complex N-glycosylation pattern of the antibodies analyzed. 
It is characterized by a large amount of hybrid structures and by oligomannose and several 
sialic acid moieties carrying glycans. The glycosylation consists of 5 % oligomannose 
structures and 5 % non fucosylated hybrid structures. Complex variants account for 4 % of all 
glycans. Fucosylated hybrid glycans account for 5 %. Complex fucosylated glycans account 
for 85 % and the sialylation level is rather high at 5 % for this mAb. The relative glycan 
composition of the three mAbs was calculated by using the peak area from the fluorescence 
chromatogram of the RP LC runs; for unresolved or coeluting glycans the EIC was used for 
integration. The N-glycan structures assigned to each numbered peak are illustrated in 
Figure 3. 
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Figure 11: RP FLD chromatogram obtained from mAb3 N-glycans after labeling with 2-AA. Peaks 
identified by MS and MS
2
 are numbered and are listed in Table 1. The appropriate 2-AA glycans are shown 
in Figure 3. The magnified view (small window) of the chromatogram shows the smaller peaks. Stacked 
numbering indicates co-elution of N-glycans. 
  
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 2 
38 
 
2.3.7. Qualification of the method 
The method was qualified to demonstrate its robustness and reliability. Sample preparation 
including deglycosylation by use of PNGaseF, N-glycan separation by ultrafiltration, N-glycan 
labeling using 2-AB and the gel filtration step to remove excess label is a standard company 
procedure which has been reported elsewhere (23). Reproducibility of fluorescence labeling 
by 2-AA was monitored by performing the two labeling reactions in parallel and by comparing 
the relative amounts of glycans. Robustness and linearity were assessed by testing different 
column batches and by analyzing dilutions of analyte (e.g. mAb1 total peak area R2 = 0.9992) 
respectively. Intra assay precision was monitored by repeated sample preparation and 
analysis by the same operator. For example, for relative quantification of mAb2 glycans by 
fluorescence coefficient of variation (%CV) values were calculated (e.g. peaks 22 (1.24 %), 
63 (1.17 %) and total glycan area (5.42 %)). All HPLC and MS experiments were conducted 
with qualified instruments. 
 
 
Table 2: Comparison of fluorescence and MS data of 2-AA labeled mAb2. Relative amounts of glycans 
derived from the fluorescence signal (upper panel) and the MS data (lower panel) are listed for the 
appropriate peak number. 
Peak# 5 6 10 7 13 11 8 9 20 22 14 25 28 29 
FLD 0.07 0.22 0.02 0.17 1.29 0.15 0.02 0.05 0.22 4.08 0.11 0.02 0.72 0.06 
MS 0.08 0.22 0.03 0.15 1.12 0.26 0.07 0.08 0.27 4.37 0.14 0.03 0.66 0.17 
Peak# 33 37 46 48 54 53 61 62 63 36 50 52 59 60 
FLD 0.83 0.01 0.23 0.20 0.96 0.12 12.96 2.73 70.06 0.32 4.27 
MS 1.20 0.10 0.05 0.08 0.79 0.08 12.95 5.29 67.43 0.26 0.15 0.18 2.42 1.37 
 
 
2.4. Conclusion 
This glycan-mapping method using RP HPLC of 2-AB or 2-AA labeled N-glycans in 
combination with fluorescence detection and on-line ion-trap mass spectrometry enables 
high sensitivity and high-resolution N-glycan analysis. The 2-AA method enables analysis of 
neutral and acidic N-glycans with positive ESI MS. Compared with the RP LC-MS of 2-AB 
labeled N-glycans more structural isomers can be separated in a shorter analysis time. In 
particular separation of the highly abundant and isobaric G1F isomers was achieved. 
Additionally, the 2-AA chromatogram of the mAb glycan standard (Figure 2) also contains 
more peaks and partially resolved peaks, because of the greater selectivity and resolution of 
the method. This selectivity of the reversed-phase chromatography in combination with 2-AA 
labeling enables separation of a variety of structural isomers of different types of N-glycans 
and, more important, separates the N-glycans into seven different groups, oligomannose, 
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hybrid and complex without core fucosylation, hybrid and complex with core fucosylation and 
two sialic acid-containing groups again with and without the core fucose residues; this 
enables rapid screening of the glycan composition. The ability to separate N-glycans with 
multiple sialic acids and up to four antennae shows the versatility of the method. Retention of 
2-AA on the reversed phase is better than that of 2-AB; this may result from the greater 
hydrophobicity of the protonated carboxyl group of the 2-AA label in the acidic mobile phase. 
The better retention and separation results in sharper peaks and because of the higher 
sensitivity in fluorescence detection of 2-AA (19, 31), analysis of rare glycan species 
becomes possible. In addition, focusing of the analyte on the column leads to a more 
concentrated sample entering the ionization chamber of the mass spectrometer and enables 
efficient ionization and more sensitive MS detection. Fragmentation of the mostly [M+2H]2+ 
ions by CID produces the mainly occurring B and Y ions providing information about the N-
glycan structure. We observed good ionization of the 2-AA labeled N-glycans in positive ESI-
MS and even for sialylated structures the MS signal was intense and on-line MS2 data were 
obtained. Because of the high resolution of the liquid chromatography and the sensitive MS 
detection, the high complexity of mAb N-glycosylation can be investigated in detail. The large 
injection volume even enables the detection and quantification N-glycans of very low 
abundance. Analysis of three mAbs with different glycosylation patterns showed the flexibility 
of the method for mAb N-glycan characterization. Furthermore, our data show that relative 
quantification with FLD data is comparable with quantification by MS for the labeled mAb N-
glycans; this was somewhat expected, because the molecular composition of the glycans is 
similar and the masses are distributed over a relatively small range. The low hydrophobicity 
of the labeled glycans, which enables good separation, also makes MS quantification more 
accurate, because the ACN content changes slowly and conditions in the ionization chamber 
of the mass spectrometer during analyte elution are almost identical. Co-eluting glycans 
could also be quantified individually by use of MS data. For samples containing N-glycans 
with a larger size distribution, however, the comparability must be evaluated individually. To 
summarize,, our 2-AA RP LC-MS approach can be used as a robust method which is 
orthogonal to the widely established HILIC of 2-AB glycans or MALDI MS of labeled neutral 
and acidic N-glycans derived from mAbs and other glycoproteins. In this work we 
demonstrated the strength and versatility of RP LC with on-line MS detection for analysis of 
N-glycosylation. 
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Abstract 
N-glycosylation is a complex post-translational modification with potential effects on the 
efficacy and safety of therapeutic proteins and known influence on the effector function of 
biopharmaceutical monoclonal antibodies (mAbs). Comprehensive characterization of N-
glycosylation is therefore important in biopharmaceutical development. In early development, 
e.g. during pool or clone selection, however, only minute protein amounts of multiple 
samples are available for analytics. High sensitivity and high throughput methods are thus 
needed. An approach based on 96-well plate sample preparation and nanoLC-MS of 2- 
anthranilic acid or 2-aminobenzoic acid (AA) labeled N-glycans for the characterization of 
biopharmaceuticals in early development is reported here. With this approach, 192 samples 
can be processed simultaneously from complex matrices (e.g., cell culture supernatant) to 
purified 2-AA glycans, which are then analyzed by reversed phase nanoLC-MS. Attomolar 
sensitivity has been achieved by use of nanoelectrospray ionization, resulting in detailed 
glycan maps of mAbs and fusion proteins that are exemplarily shown in this work. 
Reproducibility, robustness and linearity of the approach are demonstrated, making use in a 
routine manner during pool or clone selection possible. Other potential fields of application, 
such as glycan biomarker discovery from serum samples, are also presented. 
 
Keywords: oligosaccharide, N-glycosylation, fusion protein, therapeutic antibody, mass 
spectrometry, nanoLC, biomarker discovery  
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3.1. Introduction 
N-glycosylation, a complex post-translational modification of proteins, is of central 
importance in the research and development of therapeutic proteins. Of all approved 
recombinant biopharmaceuticals, e.g., monoclonal antibodies (mAbs), protein hormones, 
~40% are glycoproteins.(1) Characterization of N-glycosylation is important during 
biopharmaceutical process development because N-glycosylation may affect the safety or 
efficacy of a protein drug.(2–6) For mAbs, these effects are based on structural properties 
derived from the CH2 domain glycosylated at Asn297. Size and charge of attached N-glycans 
as well as terminal sugar moieties influence complement-dependent cytotoxicity (CDC) and 
antibody-dependent cell-mediated cytotoxicity (ADCC) potency of IgGs and thereby the 
overall efficacy. For example, lack of core fucose increases ADCC by improving binding to 
FcγRIIIa. Increased ADCC activity could be correlated with product safety, i.e., serious 
infections during TNF-targeted treatment in rheumatoid arthritis patients.(7) Moreover, lack of 
terminal galactose residues and the resulting terminal GlcNAc residues increase CDC by 
modulating binding to C1q.(8) Therefore, it is crucial to analyze the glycan pattern of a 
biopharmaceutical as early as possible during development to be able to modify the drug 
candidate, for example by glyco-engineering. Alterations of IgG N-glycosylation have been 
linked with aging and a variety of diseases, and distinct N-glycans are regarded as potential 
biomarkers because the interactions of IgGs and Fc-receptors influence and modulate 
immune responses.(9–16) 
N-glycosylation analysis is sophisticated because of the numerous N-glycan variants that 
may be attached to the protein molecules and the huge differences in their relative amounts. 
For example, recombinant human IgG antibodies contain up to 60 different N-glycans with 
relative amounts of individual N-glycans ranging from 0.02% for an oligomannose structure 
to more than 70% for the most abundant N-glycan, reflecting differences that cover three 
orders of magnitude.(17) Technologies frequently used for N-glycan analysis are CE, 
HPAEC-PAD, HPLC, MALDI and ESI-MS and various combinations of these 
technologies.(18) LC-MS is an advantageous combination as LC is able to separate glycan 
mixtures, after which glycan variants can be individually identified and quantified by on-line 
MS. However, for various analytical applications, conventional LC-MS is not sufficiently 
sensitive, especially for cases where sample amount is strongly limited. During early 
biopharmaceutical development (e.g., pool or clone selection), only minute amounts of 
recombinant protein from microtiter plates are usually available for protein and glycan 
analysis.  
N-glycan biomarker discovery in patients or healthy individuals is another scenario where 
sample amount is typically very limited. In proteomics, similar limitations have been 
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circumvented by reducing the dimensions of the analytical system, for example by use of 
nanoLC-MS. Literature reports of approaches for N-glycan analysis by use of nanoLC-MS 
are rare. Several investigations reported feasibility of nanoESI or nanoLC for glycan 
analysis.(19–23) Using a separation-free direct infusion nanoESI approach, Prien et al. 
quantified 2-13[C6]-AA and 2-
12[C6]-AA labeled N-glycans relatively, and demonstrated the 
usefulness of nanoESI for 2-AA glycan analysis.(22) Wuhrer et al. miniaturized HILIC-MS to 
nanoscale for oligosaccharide analysis, analyzing underivatized N-glycans with femtomolar 
sensitivity.(19) Avoiding glycan derivatization shortens sample preparation, but the benefit of 
improved MS detection due to the label is lost.(19, 24) Kalay et al. have used normal-phase 
nano scale HPLC-MS with on-line fluorescence to analyze 2-AB N-glycans.(20) However, 
their approach resulted in long and time consuming gradients to achieve a good 
chromatographic resolution. Ritamo et al. recently published on glycoanalysis utilizing nano-
reversed phase chromatography (RPC).(21) A nanoLC system was used to separate 
permethylated N-glycans, achieving separation for various structural isomers on a nano RP-
column. Permethylation of N-glycans is an orthogonal approach to labeling. But it requires 
the use of toxic reagents and also the formation of side products is rather likely which makes 
routine utilization questionable. Gong et al used multiplex tandem mass tag labeling for the 
quantification of neutral IgG N-glycans. They could demonstrate that their approach is 
suitable for the quantification of major N-glycans and highly reproducibly with linearity over 
several orders of magnitude.(23) However, their short PNGaseF incubation and sample 
preparation at elevated temperatures might result in incomplete deglycosylation and the loss 
of sialic acids.(25–27) It has been reported previously that RP-LC with on-line MS is broadly 
applicable for analysis of differently reducing-end labeled N-glycans.(17, 28, 29) For RP- LC-
MS, we have demonstrated that anthranilic acid (2-AA) as label is advantageous for glycan 
analysis.(17) The tag not only improves ionization by contribution of an additional charge 
carrying residue to the N-glycan, it also improves separation of labeled glycans on RP. The 
combination of 2-AA labeling with RP separation offers the additional advantage that 
N-glycans are separated according to their glycan type (high mannose, hybrid and complex), 
whether they carry a fucose residue at their core N-acteylglucosamine or not and according 
to their charge caused by terminal sialylation. 
Based on these findings we report in this manuscript a new RP nanoLC-MS approach to 
analyze minute amounts of glycoproteins with high sensitivity. The presented 96-well based 
sample preparation work-flow is simple, offers high throughput and can be applied during 
early biopharmaceutical development as a routine or to discover clinical relevant changes of 
N-glycosylation with high sensitivity. The method has high resolving power and separates 
many N-glycan structural isomers including multiple branched and acidic variants. In 
addition, 2-AA labeled glycans can be identified by MSn of the ion-trap mass spectrometer. 
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An overall sensitivity for a single N-glycan on column of ~ 400 attomol (amol) was observed 
with the recently introduced MS source. Furthermore, we demonstrate that the method is 
feasible for N-glycan characterization of minute amounts of mAbs, as well as for N-glycan 
biomarker discovery. This is shown by comparing the N-glycosylation of an Fc containing 
therapeutic protein from different cell clones and the method’s broad applicability is 
demonstrated by glycan analysis of IgGs from human serum. The approach is versatile and 
due to the use of RPC it should be applicable in many analytical laboratories already working 
with nanoLC-MS with little effort.  
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3.2. Material and Methods 
3.2.1. Materials 
PNGaseF (Roche; 11365177001). Acetonitrile (1.00030.2500) and acetic acid 
(1.00063.1000) were from Merck. Formic acid (94318), picolineborane, RNase B (R1153) 
and DMSO (41647) were from Sigma. Protein A Sepharose (17-1297-03), Protein G 
Sepharose (17-0618-05) and Sephadex® G-10 96-well plats (custom made) were from GE 
Healthcare. AcroPrep™ Advance Omega™ 10K 96-well filter plates (518-0032) were from 
Pall. Human serum was from Lonza. MAbs and cell culture supernatants were obtained from 
in-house development at Sandoz. G0F glycan standard was from Dextra. Complex and 
acidic N-glycan standards were from TheraProtein. 
 
3.2.2. Methods 
 
3.2.2.1. Purification of IgGs from human serum or cell culture supernatant 
Protein G and Protein A Sepharose were used to purify IgG from human pooled serum or cell 
culture supernatant. A centrifuge with a rotor for 96-well plates (Eppendorf) was used to force 
liquid through the filter-plates. Serum or cell culture supernatant was applied to a 96-well 
filter-plate well containing Protein A or Protein G Sepharose, respectively. 
3.2.2.2. Enzymatic N-glycan release by use of PNGaseF 
After intensive washing of immobilized IgGs or fusion proteins with PBS N-glycans were 
enzymatically released with use of PNGaseF and incubation over-night at 37°C. Released N-
glycans were separated from remaining proteins by ultrafiltration using 10K filter plates. 
Purified N-glycans were brought to dryness in a vacuum centrifuge (Christ RVC 2-25). 
3.2.2.3. Fluorescence labeling of released N-glycans or N-glycan standards 
Picolineborane and 2-AA were dissolved in 70% DMSO / 30% acetic acid (v/v) to obtain 
concentrations of 100 mg/ml and 50 mg/ml, respectively. Labeling solution (15 µl) and 
deionized H2O (10 µl) were added to either dried N-glycans or lyophilized N-glycan 
standards. The labeling reaction was performed at 37 °C for 17 h. Excess label was 
subsequently removed by gel filtration in Sephadex™ G-10 96-well plates. Columns were 
equilibrated with H2O (800 µl). Samples were filled up to 100 µl with deionized H2O and the 
sample was applied to the column. After washing with 100 µl of H2O, 2-AA labeled N-glycans 
were finally eluted with 150 µl of H2O. 
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3.2.2.4. NanoLC of labeled N-Glycans 
NanoLC (Thermo/Dionex Ultimate 3000) was set-up in “direct injection onto a nano column” 
mode according to the manufacturer manual. Column compartment with a RP-column 
(Dionex Acclaim Pepmap 25cm; 75µm I.D.) was held at 40 °C. Mobile phase A consisted of 
0.5% formic acid. Mobile Phase B consisted of 0.5% formic acid in 50% ACN. The column 
was equilibrated with 2% B at a flow rate of 300 nl/min. With a user-defined injection routine, 
1-4 µl sample were stacked between loading solution (0.1% formic acid, 1% ACN in ultrapure 
H2O) in a 20 µl sample loop. Sample loop was switched for 5-15 min, depending on the 
injected sample volume, in-line to allow the sample to enter the flow, after which the sample 
loop was switched back to load position to avoid additional gradient delay. Prior to the next 
injection sample, the loop was washed with loading solution. After sample injection, mobile 
phase B was raised to 30% over 60 min, then to 95% over 5 min. After holding at 95% B for 
5 min, the column was finally re-equilibrated with 2% B for 15 min. Eluting 2-AA N-glycans 
were detected at 254nm using the variable wavelength detector (Dionex Ultimate 3000 VWD-
3400RS with a 3 nl flow cell). 
3.2.2.5. Mass Spectrometry 
The outlet of the nanoLC was directly coupled to an ion trap ESI-MS (Bruker AmaZon) 
equipped with a recently marketed on-line nano source (Bruker CaptiveSpray 
NanoBooster™). The ion trap was operated in Enhanced Resolution Mode with a capillary 
voltage of 1.7 kV. Source temperature was set to 200 °C and a dry gas flow of 3 l/min was 
used to heat the nano source. MS² and MS³ spectra were generated with the Auto MS² 
mode, Auto MS³ mode and Collision Induced Dissociation (CID). Ion charge control was set 
to a target value of 2x105 and a maximal accumulation time of 200 ms. 
  
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 3 
49 
 
3.3. Results  
3.3.1. Method development 
N-glycosylation analysis of glycoproteins can be performed in different ways by LC-MS: the 
intact proteins, proteolytic digests or released N-glycans can be analyzed. Released glycans 
can be derivatized to even the ionization efficiency and thereby to improve the accuracy of 
quantification. This approach provides excellent coverage of the N-glycosylation pattern. We 
reported previously a method to identify and quantify 2-AA labeled N-glycans by ion-trap MS 
after RPC.(17) The method is selective for many N-glycan isomers and its robustness and 
reproducibility have been demonstrated. However, the method was developed to analyze N-
glycans of mAbs in advanced development stages, not for early development when limited 
sample amounts are available and higher sensitivity is required. Thus, we have started to 
develop a nanoLC-MS method. 
Our approach used glycans released from RNase B (Figure S1 and Table S1), a model 
protein for N-glycosylation analysis. RNase B N-glycans were prepared as described in the 
methods section, and the labeled and purified N-glycans were analyzed by nanoLC-MS. The 
nanoLC was configured in “direct injection on a nano column” mode because highly 
hydrophilic 2-AA N-glycans like the high mannose type glycans did not bind properly to the 
trapping column, and were therefore underrepresented in setups that included a pre-
concentration step with a trapping column. The user defined injection routine allows injection 
volumes from 1 to 4 µl without major gradient delay. This is achieved by, depending on the 
chosen injection volume, switching the sample loop between 5 to 15 min into the flow to 
ensure that the entire sample leaves the loop before switching it back to loading position. 
Because of the direct injection, samples must be highly purified to avoid salt plugs entering 
the nanospray chamber of the MS, which may damage the emitter tip and shorten its lifetime. 
The chosen acidic mobile phases resulted in high selectivity for many glycan isomers on RP 
and improved ionization of glycans in the positive ionization mode. The portion of formic acid 
in the mobile phase could be lowered to 0.5% compared with 1% for the LC-MS method, 
which may be due to the more efficient ionization in the nano spray. The 2-AA glycans 
occurred mostly as double [M+2H]2+ charged ions, 2-AA N-glycans smaller than 1500 Da 
occurred as single [M+H]1+ charged ions. In addition along with protonated ions, mixed 
adduct ions with sodium (e.g., [M+H+Na]2+) or potassium (e.g., [M+H+K]2+) were also 
present. The 2-AA glycans were identified by MS, MS² and MS³. In addition to RNase B, the 
method was tested with multiply branched and sialylated glycans to cover all types of 
glycans. Therefore, several N-glycan standards were labeled with 2-AA and analyzed (Figure 
S2). All types of N-glycans can be identified and quantified with this new approach, which is 
in agreement with our previously reported RP LC-MS approach. (17) High mannose glycans 
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elute first, followed by non-fucosylated hybrid and complex variants, then fucosylated hybrid 
and complex glycans. The overall chromatographic resolution is higher for the nanoLC 
approach compared with the LC-MS approach. 
As described in the introduction, the amount of sample available can be very limited at 
various stages of biopharmaceutical development, especially during early development 
phases like pool or clone selection. During clone selection, numerous samples in complex 
matrices (cell culture supernatant) must be analyzed, making affinity purification necessary. 
Therefore, sample preparation had to be adapted to increase throughput and include affinity 
purification steps. 96-well plate-based sample preparation is a viable option, the success of 
which has already been demonstrated for glycoprotein analytics.(10, 15, 30) We selected a 
centrifugation-based 96-well filter plate sample preparation because we had observed 
inhomogeneous flow through the small scale columns in the filter plate wells on a vacuum 
manifold. Protein A Sepharose, which is commercially available and state-of-the-art for 
downstream processing of Fc-part containing biopharmaceuticals (mAbs and fusion 
proteins), F was used as affinity resin. The schematic work-flow is illustrated in Figure 1. 
Deglycosylation with PNGaseF was performed “on-column”. After washing of bound mAb, N-
glycans were released by incubation of the Protein A-mAb complex with PNGaseF at 37 °C 
followed by elution with H2O, which resulted in higher glycan yields than mAb elution followed 
by PNGaseF digestion in solution. PNGaseF was subsequently removed by ultrafiltration. 
Glycans were dried by vacuum centrifugation and 2-AA labeling was performed via reductive 
amination by use of the non-toxic reductive agent picoline borane.(31) Excess label was 
removed by small scale gel filtration, which was performed in custom-made 96-well plates 
with Sephadex G-10 resin. The last step is a downscaled procedure based on a previously 
published purification approach.(17, 27) This purification is highly efficient because it 
separates labeled N-glycans from excess 2-AA in a single centrifugation step.  
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Figure 1: Schematic work-flow. Up to 2x 96 samples can be handled simultaneously. Immobilized Protein 
A or Protein G is used to capture mAbs, Fc-containing fusion proteins or other IgGs with high specificity. 
Immobilized target is then highly efficiently deglycosylated with the use of PNGaseF. Released N-Glyans 
are labeled with 2-AA via reductive amination after ultrafiltration to remove remaining proteins. Labeled 
and purified 2-AA glycans are identified and quantified by RP nanoLC-MS by use of an ion-trap mass 
spectrometer. 
 
3.3.2. Qualification of the approach 
Several parameters, e.g., sensitivity, robustness, linearity, reproducibility, were investigated 
to qualify the nanoLC-MS method. Different column batches were tested and the method 
was executed on different days and by different operators. To determine overall sensitivity 
and linearity of the method N-glycan standard G0F was labeled with 2-AA as described in the 
methods section and serial dilutions were prepared to obtain concentrations ranging from ~ 
2.2 pmol/µl to 200 amol/µl. One µl of each dilution was injected. EIC peak areas of 2-AA G0F 
were used for data interpretation (Figure S3 A). Example MS spectra are shown in Figure 
S4. EICs of the four smallest amounts that are still in the linear range are shown in magnified 
view (Figure S3 B). Peak areas were plotted against glycan amount (Figure S3 C and Figure 
S3 D) and linearity was evaluated by linear regression with R²=0.9988, indicating good linear 
correlation between 2.2 pmol and 800 amol. Injections with 600 and 400 amol 2-AA G0F 
were still detected, but were not in the linear range. The 200 amol 2-AA G0F injections were 
not detected anymore. The overall detection limit was thus ~ 400 amol 2-AA G0F glycan on 
column, and the lower limit of quantification (LLOQ) was 800 amol. 
Subsequently, the complete method including sample preparation was validated. 
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Reproducibility and robustness were assessed, for example, by comparing results of two 
different operators (Table S2). With the determined sensitivity, it is possible to analyze all N-
glycans of an IgG using less than 1 µg protein. Varying ionization efficiencies among different 
N-glycan types was reported previously, especially differences between neutral and 
sialylated glycans. (24) In an earlier work we demonstrated that quantification by 
fluorescence and MS is identical for neutral N-glycans. (17) To further qualify our 
quantification by MS for acidic N-glycans, we compared the quantitative MS data of three N-
glycans, the neutral G2F structure and the single and double sialylated glycans SG2F and 
S2G2F obtained from a fusion protein with high sialylation to the percentages obtained from 
the highly sensitive UV-cell in the same nanoLC-MS run (Figure S5). The SG2F glycan has a 
lower percentage when determined by MS (MS: 44%; UV: 52%) which might be due to loss 
of the sialic acid as a small G2F peak is visible under the SG2F peak (Figure S5A). However, 
for the double sialylated structure S2G2F, the quantity relative to G2F is identical for MS and 
UV quantification. These findings show that relative quantification by MS is possible and 
reliable with the developed method, especially for the intended relative comparison of 
different pools or clones with the same method. 
 
Figure 2: NanoLC-MS glycan map of a monoclonal antibody. 1.6 pmol of 2-AA labeled N-glycans 
corresponding to ~ 120 ng antibody were used for analysis. EICs of the 2-AA labeled N-glycans are 
depicted. Complete glycan map (A) and magnified view (B) are shown. Peaks are numbered in elution 
order. Identified glycans are listed in Table 1, glycan structures are depicted in Figure S6. 
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3.3.3. Glycan mapping of a monoclonal antibody 
We then demonstrated the feasibility of the method for characterization of therapeutic 
glycoproteins. The N-glycosylation pattern of a mAb was analyzed. Sample preparation was 
successfully performed with less than 1 µg mAb from a drug product formulation. 
Approximately 1.6 pmol 2-AA labeled N-glycans, corresponding to 800 fmol or 120 ng mAb 
were finally injected after sample preparation. The resulting EIC is shown in Figure 2. The 
most abundant oligosaccharides are complex type N-glycans, G0F followed by the two G1F 
isomers with 1,3 and 1,6 galactosylation, respectively. Minor abundant species are shown in 
magnified view (Figure 2B). Identified N-glycans and relative N-glycan composition of the 
mAb are listed in Table 1. The absolute N-glycan amounts range from ~ 640 amol for a M7 
isomer to 1.1 pmol for the most abundant G0F glycan, again showing the huge differences in 
relative glycan amounts and the resulting requirements to the method in terms of linearity 
and sensitivity. Listed structures in Table 1 are deduced from their mass and from MS², as 
well as from MS³ data. For example, the peaks 13, 14 and 15 have the same mass and are 
not distinguishable by MS2 or MS3. Peaks 13 and 14 correspond to G1F with the terminal 
galactose residue on the 1,3 arm or 1,6 arm, respectively, and the separated peak 15, also 
named G1F, might be a truncated bi-secting or tri-antennary variant with the same number of 
sugar moieties, but not a third G1F isomer. As described above, the elution order of 2-AA 
glycans is similar to the pattern obtained by RP LC-MS. More hydrophilic oligomannose 
structures elute first, followed by non-fucosylated complex variants. Hybrid structures elute 
before complex type structures as observed for fucosylated glycan structures. Assigned 
glycan structures are shown in Figure S6. 
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Table 1: 2-AA glycans observed in the glycan map of a monoclonal antibody. Glycan structures were 
identified from their mass and their fragmentation by MS/MS. Theoretical and by ion-trap MS measured 
values are given. Composition of the N-glycans with their respective portion is depicted on the right. 
Glycan map – monoclonal antibody 
 
Mass 
  
# Measured Calculated Structure Portion 
1 1679.45 1679.59 M7 0.07% 
2 1679.46 1679.59 M7 0.12% 
3 1517.53 1517.54 M6 0.84% 
4 1679.47 1679.59 M7 0.04% 
5 1679.46 1679.59 M7 0.06% 
6 1355.46 1355.49 M5 2.13% 
7 1599.49 1599.59 G1 0.07% 
8 1437.48 1437.54 G0 0.55% 
9 1031.34 1031.38 M3 0.23% 
10 1907.57 1907.70 G2F 0.95% 
11 1948.57 1948.73 A3G1F 0.55% 
12 1866.53 1866.68 M5G1F 0.15% 
13 1745.52 1745.65 G1F 13.39% 
14 1745.61 1745.65 G1F 4.45% 
15 1745.56 1745.65 G1F 1.02% 
16 1542.50 1542.57 M3G1F 1.02% 
17 1380.36 1380.52 M3G0F 2.41% 
18 1583.58 1583.60 G0F 71.52% 
19 1786.57 1786.68 G0FB 0.10% 
20 1948.59 1948.73 G1FB 0.33% 
 
 
3.3.4. Application during early biopharmaceutical development 
Central goal of our investigation was a glycan characterization approach that can be used in 
a routine manner during clone selection. In early stages of biopharmaceutical development, 
protein producing cells (clones) are cultivated in microtiter plates in a few hundred microliters 
of medium and titers around 1 mg/ml. The aim of this procedure is to identify a clone with 
appropriate characteristics, for example, distinct protein and glyco-variants and a high titer. 
Clones must be analyzed comprehensively, but characterization is difficult because as many 
different aspects of the biopharmaceutical candidate as possible have to be analyzed, hence 
only minute amounts can be used for each analysis. With the presented work-flow, it is 
possible to characterize N-glycosylation patterns during clone selection employing only 
minute amounts of protein. Different clones of an Fc-part containing fusion protein from early 
development were used to demonstrate the feasibility. 
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Figure 3: Glycan map of four Fc containing therapeutic proteins derived from clone selection phase 
determined by nanoLC-MS after small scale sample preparation. Clones 1-4 are shown exemplarily. A) 
Percentages of the different glycoforms are shown. Error bars indicate variability of the method. 
Glycosylation pattern of the four clones is similar. B) Magnified view shows the minor abundant N-
glycans 
 
Cell culture supernatants from different clones with concentrations between 0.3 mg/ml and 
1.7 mg/ml were analyzed. Sample preparation was performed with immobilized Protein A as 
described in the methods section and shown in Figure 1. Supernatant (5 µl) from each clone 
sample containing between 1.5 µg and 8 µg fusion protein, respectively, was mixed with 45 
µl PBS before sample preparation. Between 0.27 and 1.5 pmol glycans were injected from 
each sample, depending on the titer. Detailed glycan maps of four different clones based on 
EICs are shown exemplarily in Figure 3. Small differences between the clones can be 
observed, which demonstrates the need for a sensitive, precise and accurate method to 
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differentiate the clones. Major abundant N-glycans are present in all four clone samples. 
Some minor abundant N-glycans are absent in some clones and some structures are present 
only in one clone sample, e.g., SA3F is exclusively present in clone 4. Relative distribution of 
N-glycan types is also comparable. Clone 1 and clone 2 have 2% oligomannose structures 
and clone 3 and clone 4 have 1% oligomannose structures. Clone 1 has 47.9% terminal 
galactosylation and 20.6% terminal sialic acids. Clone 2 has 44.8% terminal galactosylation 
and 21.4% terminal sialic acids. Clone 3 has slightly less terminal galactosylation and 
sialylation with 36.9% and 17.5%, respectively. Clone 4 has the highest portion of terminal 
galactosylation (51.7%) and terminal sialylation (24.1%). These results demonstrate that this 
robust nanoLC-MS methodology can be used to characterize N-glycans in very early 
biotechnological development. To further qualify the approach the glycan maps obtained with 
the newly developed 96-well approach are compared to glycan maps from the same clones 
after conventional downstream processing (DSP) using Protein A columns. Sample 
preparation including glycan labeling was performed as described earlier.(17) Figure 4 shows 
the correlation plots of glycan maps. The N-glycan pattern are highly similar to the one 
obtained using the 96-well-based approach. The plots show the linear correlation of the two 
methods. These findings further demonstrate the potential of the developed approach in 
biopharmaceutical development. 
 
Figure 4: Correlation plots comparing glycan maps of four clones after downstream processing to glycan 
maps obtained with the newly developed 96-well based nanoLC-MS analysis. Most abundant N-glycans 
are labeled and linear correlation coefficients are depicted. Insets show the minor abundant N-glycans. 
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3.3.5. Investigation of serum IgG N-glycans 
Application of this new approach is not limited to characterization of biopharmaceutical 
products and product candidates. Due to its high reproducibility, application in biomarker 
discovery investigations is possible. Changes in N-glycosylation of glycoproteins such as 
IgGs have been connected to various diseases and aging in several investigations.(13–16) 
As described in the introduction, terminal galactosylation or fucosylation influence 
interactions between IgG molecules and Fc-receptors, which in turn affects immune 
response. This may influence progression, prognosis or outcome of certain diseases. The 
presented work-flow can be used to screen large populations of patients or healthy subjects 
for significant differences in their respective N-glycosylation. The high resolving power of the 
nanoLC-MS method and the order of 2-AA N-glycan elution from the RP column according to 
their glycan type (e.g., oligomannose, hybrid and complex with and without fucosylation or 
acidic glycans) allow rapid semi-automatic interpretation of the nanoLC-MS runs. To 
demonstrate applicability of the method for glycan biomarker discovery, human IgG N-
glycosylation was investigated. IgGs were purified from 5 µl of pooled human serum with an 
estimated IgG concentration of 10 mg/ml with immobilized Protein G Sepharose. In contrast 
to the above described experiments, the resin was changed from Protein A to Protein G, 
which allows selective purification of all IgG subclasses 1, 2, 3 and 4. Protein A has no 
affinity to IgG3 and variable affinity to IgA and IgM, and it is therefore of limited use for this 
specific study. After Protein G affinity isolation and subsequent sample preparation, a total 
amount of ~ 4 pmol 2-AA labeled glycans was analyzed by nanoLC-MS. 
 
Figure 5: Glycan map of human serum IgGs. (A) EICs of the various 2-AA labeled N-glycans are shown. 
Peak numbering is according to elution order. Table 2 lists the identified glycans and their relative 
amount and Figure S6 shows the glycan structures. 
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Resulting chromatograms based on the EICs of the 2-AA N-glycans are shown in Figure 5. A 
total of 28 different glycoforms were identified and quantified. Detected glycans, relative 
glycan composition and the retention time relative to most abundant G0F glycans are listed 
in Table 2; appropriate glycan structures are shown in Figure S6. The majority of detected N-
glycans carry a core fucose, and a small portion carries one to two terminal sialic acids. 
Complex biantennary glycans carrying a core fucose are the most abundant glycans, 
comprising more than 70%. Double fucosylated glycan species as G1F2 or G2F2 (Figure S7) 
were also found during our investigations and were identified by MS² by their signature 
fragments. These findings correspond to previous reports.(32) 
Table 2: 2-AA labeled N-glycans identified from human serum IgGs. Assigned N-glycans identified by MS, MS
2
 and MS
3
 
are listed. Relative retention time to most abundant G0F and the portion is depicted, as well as the portion for each 
glycoform. 
Glycan Map – Human serum IgGs 
# Rel. Ret.Time Structure MS (Mean %) 
1 0.85 M5 0.06% 
2 0.86 G2 0.52% 
3 0.88 G1 0.99% 
4 0.89 G0 0.38% 
5 0.94 G3F 0.01% 
6 0.94 G1B 0.21% 
7 0.95 G2F 0.07% 
8 0.95 G0B 0.12% 
9 0.95 G2F2 0.01% 
10 0.96 G1F2 0.01% 
11 0.97 G2F 12.69% 
12 0.98 G1F 22.29% 
13 0.99 G1F 9.31% 
14 0.99 SG2 0.24% 
15 1.00 G0F 30.08% 
16 1.02 G2FB 0.82% 
17 1.03 G1FB 0.43% 
18 1.04 G1FB 6.38% 
19 1.05 G0FB 8.09% 
20 1.09 SG2F 3.39% 
21 1.12 SG1F 1.60% 
22 1.12 SA3G2F 0.24% 
23 1.12 SG1F 0.23% 
24 1.12 SM3G1F 0.36% 
25 1.14 S2G2 0.36% 
26 1.17 SA3G1F 0.11% 
27 1.24 S2G2F 0.45% 
28 1.26 S2A3G2F 0.55% 
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With the use of relative retention times and separated 2-AA N-glycans in groups, rapid 
screening of the N-glycan type composition can be done semi-automatically by integration of 
the appropriate region of the chromatogram. For example, content of sialic acid-containing 
and core fucosylated 2-AA glycans can be quantified by integration of peaks between 1.09 
and 1.26 relative retention times. With the same methodology, e.g., the degree of 
fucosylation, which has been associated with certain types of cancer, can be determined. 
(33) The approach is not limited to IgGs. By adjusting sample preparation, other target 
proteins or protein mixtures can be investigated. These results also show that N-glycan 
biomarker investigation can be performed with the presented approach. 
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3.4. Discussion 
Starting with RNase B (Figure S1) and several glycan standards (Figure S2), a new 
methodology that enables sensitive and selective analysis of less than 1 µg glycoprotein with 
linearity over several orders of magnitude and high sensitivity for single glycans in the 
attomolar range has been developed. Compared to a previous publication that reported MS 
detection of underivatized N-glycans with low femtomolar sensitivity, the presented approach 
has improved sensitivity, which is most likely due to the applied 2-AA labeling.(19) In 
comparison with the HILIC nanoLC-MS of Kalay et al., a shorter run time with equal or even 
better chromatographic resolving power was achieved with the RP approach reported 
here.(20) 
Using our technology, many glycan isomers could be differentiated and different kinds of 
samples were successfully analyzed with minimal sample consumption. The feasibility of the 
approach was demonstrated with N-glycan characterization of 160 ng mAb from a drug 
product formulation with high sensitivity. High sample throughput has been achieved with this 
96-well plate sample preparation. A previously published highly efficient gel filtration step has 
been successfully miniaturized.(17, 27) This purification step desalts 2-AA glycans efficiently 
and removes excess label in a single step. Robustness and reproducibility were 
demonstrated. Requirements for routine use in early biopharmaceutical development are 
fulfilled, which is shown with the glycan mapping results of clone selection samples. Minor 
differences in N-glycosylation of a fusion protein from different clones have been detected, 
which allows early guidance for further development with respect to N-glycosylation. 
Comparison with glycan maps derived from the same clone samples after conventional 
downstream processing demonstrated highly similar results. 
The nanoLC-MS method has been developed to quantify all types of N-glycans. The formic 
acid content of the mobile phase was raised to 0.5%. At this concentration sialic acids of N-
glycans are mainly protonated and therefore behave like neutral glycans, which enhanced 
MS intensities in positive ionization mode. Furthermore the used nanoESI source greatly 
improved and equalized ionization of the labeled N-glycans which was demonstrated by 
comparing UV to MS data. This ability to identify and quantify all different types of N-glycans, 
including multiply branched and sialylated variants, facilitates broad application in different 
areas of glycobiology. One further possible application has been shown exemplarily with the 
serum IgG glycan biomarker experiment. Results are in good agreement with a previously 
published investigation by Flynn et al.(32) 
Compared to other recently published high throughput glycan analysis approaches that are 
also based on 96-well plate sample preparation, (34, 35) the methodology reported here, 
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which uses 2-AA instead of 2-AB and RP nanoLC-MS instead of UPLC or MALDI MS, results 
in an up to ten-fold higher sensitivity based on the initial glycoprotein amounts. Higher 
coverage of the glycan maps is also achieved due to the ability to reliable quantify minor 
abundant N-glycans. To summarize, the presented method demonstrates the power of RP 
nanoLC-MS for N-glycosylation analysis. In combination with the high throughput 96-well 
plate sample preparation procedure N-glycan characterization can be performed in a routine 
manner during early biopharmaceutical development. The versatility of the method was 
demonstrated with several different possible fields of application. 
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Small scale affinity purification and high sensitivity 
reversed phase nanoLC-MS N-glycan 
characterization of mAbs and fusion proteins 
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Figure S1: Extracted Ion chromatograms of 2-AA labeled N-glycans derived from RNAse B. Peaks are 
numbered by elution order. Identified glycans are listed in Table S1 
 
 
Table S1: RNaseB glycans identified by MS and MS². Figure S1 shows the corresponding chromatogram. 
# 1 2 3 4 5 6 7 8 9 10 11 12 
Glycan M8 M7 M7 M6 M4 M5 G2 M6G0 M6 M5G1 G2F G1F 
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Figure S2: Analysis of highly acidic and multiply branched N-glycan standards. Overlay of EICs from 
different 2-AA labled glycan standards is shown. Each standard was analyzed individually. N-glycan 
structures corresponding to the peak numbering are depicted on the left. For N-glycans with several 
structural isomers one possible structure is shown.  
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Figure S3: Determining linearity and limits of the method by use of 2-AA labeled G0F standard in a serial 
dilution. (A) EICs of injections from 2200 fmol to 2 fmol. Peaks had a constant retention time around 55 
minutes. (B) Magnified view of the four lowest amounts. (C) Peak areas of EICs are plotted against the 
glycan amount on column to show the linear correlation. 800 amol was the lowest amount that fitted the 
linear regression. 600 and 400 amol were also detectable, but did not fit linear regression. 800 amol is the 
lowest amount for reliable quantification, the lower limit of quantification. (D) Magnified view of four 
lowest injection amounts (22 fmol – 0.8 fmol) that fitted into the linear regression. 
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Figure S4: MS spectra of high and low G0F 2-AA dilutions. (A) MS spectrum of 1.1 pmol injection showing 
the [M+H]
2+
 ion at 792.7 m/z. (B) MS spectrum of 2.2 fmol injection. [M+H]
2+
 ion at 792.7 m/z is clearly 
visible with good S/N. (C) Exemplary isotopic pattern of double charged 2-AA G0F at 792.7 m/z. 
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Figure S5: Comparison of MS quantitation to UV quantitation of neutral and acidic N-glycans. (A) MS 
quantification based on the EIC peak areas of G2F (neutral), SG2F (one sialic acid) and S2G2F (two sialic 
acids). (B) UV quantification based on peak areas of the three N-glycans. Only the three labeled peaks of 
the chromatogram from glycans of a fusion protein were integrated for comparison. (C) Mass spectra of 
the three analyzed N-glycans. 
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Figure S6: Glycan structures found in serum IgGs and the monoclonal antibody. N-Acetylglucosamine 
(blue), Galactose (yellow), Mannose (green), Fucose (red), N-Acetylneuraminic acid (purple). For glycan 
structures with several isomers only one possible structure is depicted exemplarily. 
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Table S2 Robustness of the developed approach for the glycan map of a monoclonal antibody. Sample 
preparation and nanoLC-MS was performed by two different operators on different days in the same 
laboratory on the same nanoLC-MS system. For better comparison relative retention times (Rel. RT) 
based on most abundant G0F are listed. Rel. RT and relative glycan amounts are in good agreement 
between the two operators. 
 
Operator 1 Operator 2 
 
 
  
  Glycan Rel. RT MS % Rel. RT MS % 
M7 (1) 0,77 0,11% 0,78 0,10% 
M7 (2) 0,78 0,15% 0,79 0,10% 
M6 0,80 0,58% 0,81 0,64% 
M7 (3) 0,81 <0,10% 0,82 <0,10% 
M7 (4) 0,83 <0,10% 0,84 <0,10% 
M5 0,85 2,28% 0,85 2,64% 
G1 0,88 0,04% 0,88 0,12% 
G0 0,89 0,46% 0,90 0,57% 
M3 0,90 0,76% 0,90 0,70% 
G2F 0,95 0,08% 0,95 0,10% 
M5G1F/M6G0F 0,95 0,05% 0,95 0,06% 
G2F 0,97 0,73% 0,97 1,08% 
G1F 0,97 0,52% 0,97 0,64% 
M5G1F/M6G0F 0,98 0,15% 0,98 0,20% 
G1F 0,98 11,48% 0,98 13,27% 
G1F 0,99 3,42% 0,99 4,10% 
M3G1F 0,99 1,04% 0,99 1,11% 
G0F 1,00 74,96% 1,00 71,78% 
M3G0F 1,00 2,73% 1,00 2,27% 
G1FB 1,04 0,08% 1,04 0,12% 
G0FB 1,05 0,37% 1,05 0,41% 
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Figure S7: MS² spectra of two glycans each carrying two fucose residues. (A) MS² of G2F2. Precursor ion 
was double charged 1027.8 m/z. The glycan can be identified unambiguously due to two signature 
fragments at 1689 m/z and 512 m/z respectively. (B) MS² of G1F2. Precursor ion was double charged 946.8 
m/z. This glycan can be identified according to the fragments at 512 m/z and 1527 m/z. 
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Chapter 4 
 
Development and qualification of a high-throughput 
affinity purification and N-glycan analysis 
methodology for glycan PK profiling of monoclonal 
antibodies 
 
Abstract 
In this chapter the development and qualification of an affinity purification is described. The 
method was intended to recover monoclonal antibodies from preclinical or clinical serum 
samples. The affinity purification utilized immobilized antigen columns in 96-well format and a 
selective elution step of the Fc part from selectively captured mAbs using the IdeS enzyme. 
The glycosylated antibody fragment was deglycosylated and the N-glycans were labeled with 
2-AA and finally analyzed using nanoLC-MS. The incorporation of an internal stable heavy 
isotope N-glycan standard allowed the differential analysis of individual mAb N-glycans. The 
sensitive method enabled N-glycan analysis from 50 µl serum samples containing as little as 
40 ng mAb. The approach was subsequently qualified in terms of linearity, reproducibility and 
robustness. The investigation of a simulated decrease of terminal galactosylation of a mAb 
demonstrated the viability of the developed methodology for the intended N-glycan PK 
profiling. 
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4.1. Introduction 
Affinity purification of biopharmaceuticals from complex matrices is difficult, especially the 
purification of monoclonal antibodies. In serum there is a constant IgG concentration of 
approximately 10 mg/ml, the so called baseline concentration (1, 2). The half-life of 
endogenous IgG is around 23 days which is achieved through a recycling mechanism 
involving the neonatal Fc receptor (FcRn). This process also applies for mAbs (3, 4). After 
administration of an IgG biopharmaceutical a baseline concentration increase of 
approximately 1-3 % occurs depending on the injected amount (1). Investigation of N-
glycosylation influence on the pharmacokinetics of mAbs in animal and human studies is 
reported several times in literature (5–12). For distinct glycoforms enriched IgG fractions 
were used in some studies (10, 12). However, enrichment might change the protein drug 
product and may lead to false results. Analysis of N-glycosylation from the complex 
glycosylated mAb for example by HPLC or MS is therefore advantageous. The mAb has to 
be purified from the highly complex serum matrix which can be achieved with high affinity 
using the respective antigen. However, use of 0.5 ml to 1 ml serum are reported due to the 
low mAb concentration (5–7). In addition the elution of monoclonal antibodies after binding 
their respective antigen requires harsh conditions (e.g. very low pH) which could in turn lower 
the yield (13). 
To overcome these challenges a comprehensive sample preparation is necessary. In this 
chapter a 96-well plate based affinity purification is developed to enable processing of large 
numbers of samples. Immobilized antigen is used to recover the target mAb. Instead of 
elution via pH shift, the glycosylated Fc part is released with a specific enzyme and the 
released and derivatized N-glycans analyzed by LC-MS. Quantification of proteins and 
peptides from serum is often performed using stable heavy isotope internal standards (14–
17). However, since stable heavy isotope labeling of N-glycans is hardly possible the use of 
stable heavy isotope fluorescence labels like 2-AA is a viable option for N-glycan 
quantification by mass spectrometry (18). The use of stable heavy isotope labeled 2-AA N-
glycans as internal standard levels out differences during sample preparation and different 
ionization efficiencies during mass spectrometric analysis and will be evaluated and 
implemented in the work-flow. 
It is further demonstrated that the developed method enables full mAb N-glycan 
characterization from 50 µl of serum samples with minimum concentrations of 5-10 µg/ml and 
analysis of the major glycovariants at concentrations below 1 µg/ml. The developed 
approach is finally qualified for use with two feasibility studies including linearity, 
reproducibility and robustness experiments. 
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4.2. Material and Methods 
4.2.1. Materials 
2-Aminobenzoic acid, ethanolamine, formic acid, picoline borane, DMSO, 13C aminobenzoic 
acid were purchased from Sigma (Munich, Germany),  PNGaseF from Roche (Penzberg, 
Germany), acetic acid, acetonitrile and hydrochloric acid from Merck (Darmstadt, Germany), 
Protein G sepharose, NHS activated sepharose, Sephadex® G-10 96-well plates and 96-well 
deep well plates from GE Healthcare (Munich, Germany), PBS from Gibco/Life technologies 
(Darmstadt, Germany) and Β-galactosidase from New England Biolabs (Frankfurt, Germany). 
Multicreen THS HV filter plates were obtained from Milipore, IdeS (Fabricator™) from 
Genovis (Lund, Sweden), 96-well plates from Nunc (Thermo Scientific, Germany), 
AcroPrep™ Advance Omega™ 10 kDa 96-well filter plates from Pall (Dreieich, Germany). 
4.2.2. Methods 
4.2.2.1. Preparation of heavy isotope 2-AA labeled N-glycans 
N-glycans of desalted mAb (1 mg) were released with use of PNGaseF overnight (17 h) at 
37°C. The N-glycans were separated from the proteins using Amicon 30K filter devices and 
were brought to dryness in a speedvac. Picoline borane and [13C] 2-AA were dissolved in 
70:30 (% v/v) DMSO-acetic acid to furnish concentrations of 63 and 50 mg mL-1, respectively. 
Labeling solution (15 µL) and deionized water (10 µL) were added to 15 nmol enzymatically 
released and dried glycans. The labeling reaction was performed at 37°C for 17 h. Excess 
label was removed by gel filtration on G-10 columns. Columns were conditioned with 
10 ml H2O. Samples were diluted to 100 µl with deionized H2O then applied to the column. 
After rinsing the column with 700 µl H2O the purified fluorescence labeled N-glycans were 
eluted with 600 µl H2O. Purified [13C] 2-AA labeled N-glycans were aliquoted and stored at  
-20°C until use. 
4.2.2.2. Reconstitution of antigen and preparation of stock solution 
Recombinant human antigen was reconstituted according to the manufacturer instructions. 
Antigen was dissolved in H2O (1 mg/mL) and reconstituted for 2 hours at room temperature. 
4.2.2.3. Preparation of 96-well filter plate based affinity columns 
The membranes of a 96 well filter plate were wetted with 1mM HCl (100 µL) before addition 
of 200µL NHS activated sepharose-isopropanol slurry per well. Isopropanol was removed by 
centrifugation and the columns were washed with 1 mM HCl (150 µL) for four times. Antigen 
solution (100 µL) was centrifuged into the columns and coupling reaction was allowed to take 
place for 2 hours at ambient temperature. Affinity columns were washed and remaining NHS 
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groups were inactivated with use of ethanolamine buffer (150 µL). Finally columns were 
equilibrated with PBS. 
4.2.2.4. Affinity purification of monoclonal antibodies 
Serum samples (50 µL) were diluted to 100 µL with PBS and applied to the affinity 
purification column by centrifugation. Bound mAb was washed six times with PBS to remove 
serum and unspecific bound proteins. Fabricator solution was centrifuged into the columns to 
release the glycosylated Fc part of the mAb. Reaction was performed at 37°C for 30 minutes. 
Released Fc parts were eluted with PBS and PNGaseF with 13C-2-AA labeled N-glycan 
standards was added. This mixture was incubated for 17 hours at 37°C. Remaining proteins 
were removed by ultrafiltration using 96-well plates with 10 kDa membranes. Released N-
glycans with glycan standard were dried by vacuum centrifugation. 
4.2.2.5. N-glycan labeling 
Dried samples containing free reducing end N-glycans and 13C 2-AA labeled glycan 
standard were dissolved in H2O (10µL) and 2-AA labeling solution (15 µL; 100 mg/mL 
picoline borane, 50 mg/mL 2-AA in a 7:3 mixture of DMSO and acetic acid) was added. 
Labeling reaction took place for 17 hours at 37°C. 
4.2.2.6. Gel filtration 
Custom made 96-well plate Sephadex G-10 columns were equilibrated with 800µL H2O. 
Labeled samples were filled up to 100µL with H2O and applied to the gel filtration columns. 2-
AA and 13C 2-AA labeled N-glycans were eluted with H2O (150 µL). Finally samples were 
brought to dryness by vacuum centrifugation and were redissolved in 20µL H2O for nanoLC-
MS analysis. 
4.2.2.7. Degalactosylation of monoclonal antibodies 
mAb was degalactosylated by addition of beta-galactosidase and incubation at 37°C for 1 h 
after desalting and transferred into PBS. Reaction was stopped by cooling the samples to 
4°C. 
4.2.2.8. Size Exclusion Chromatography 
Size exclusion chromatography (SEC) analysis of proteins was performed with an Agilent 
1200 series HPLC with a SEC column (Phenomenex Yarra™ SEC-3000, 4.6 mm x 30cm; 3 
µm particle size). Eluent was 150 mM potassium phosphate pH 6.5. Following sample 
injection elution was performed for 40 min at 0.4 ml/min. Column temperature was 30°C. UV 
detection was performed at 206 nm, 214 nm and 280 nm. 
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4.2.2.9. HPLC of intact proteins 
Analysis of intact proteins was performed with an Agilent 1200 series HPLC on a C8 
reversed phase chromatography column (Agilent Zorbax 300SB-C8, 2.1 x 150mm; 3.5µm 
particle size). Eluents were 0.05 % formic acid in H2O (component A) and 0.05 % formic acid 
in ACN (component B). The system was equilibrated at 26% component B. Following sample 
injection initial conditions were held for 2 min. Component B was then raised to 60 % over 18 
min and to 95% over 4 min. After column regeneration at 95% B for 4 min, the column was 
re-equilibrated at 26 % for 4 min. Flow rate was 0.35 mL min-1 oven temperature was 70°C. 
UV detection was performed at 206 nm, 214 nm and 280 nm. 
4.2.2.10. RP HPLC of 2-AA labeled glycans 
Liquid chromatography was performed with an Agilent 1200 Series chromatograph on a 
Waters Acquity UPLC BEH130 C18 (2.1 mm x 150 mm 1.7-µm particle) column. Analysis of 2-
AA labeled glycans was performed with a gradient prepared from 1.0 % formic acid in H2O 
(component A) and 50 % ACN in 1.0 % formic acid in H2O (component B). The column was 
equilibrated with 4 % B. After injection of up to 100 µL sample the mobile phase composition 
was held at 4 % B for 2 min. The proportion of B was then raised in four steps to 28%, first to 
10 % over 27 min, then to 11.5 % over 10 min, then to 14 % over 8 min and finally to 28 % 
over 19 min. The column was regenerated by increasing to 90 % B over 4 min, followed by 
isocratic elution for 2 min. The column was then re-equilibrated at 8 % B for 5 min. Oven 
temperature was 50 °C and the flow-rate was 0.30 mL min-1. Fluorescence detection was 
performed with an excitation wavelength of 250 nm and an emission wavelength of 425 nm. 
Analysis of 2-AB labeled glycans was performed with a gradient prepared from 0.5 % formic 
acid in H20 (component A) and 0.5 % formic acid and 5 % ACN in H20 (component B). The 
column was equilibrated with 25 % B. After injection the mobile phase was held at 25 % B for 
2 min, eluent B was increased to 55 % over 60 min and then increased to 61 % over 24 min. 
The composition was held for 2 min and then initial condition was reached after 2 min and 
held for additional 5 min. Oven temperature was 40°C and the flow rate was 0.3 ml min-1 
Fluorescence detection was performed with an excitation wavelength of 250 nm and an 
emission wavelength of 428 nm. 
 
4.2.2.11. nanoLC-MS of 2-AA labeled glycans 
NanoLC (Thermo/Dionex Ultimate 3000) was set-up in “preconcentration” mode according to 
the manufacturer manual with a pre-concentration column (3 µm particles, 75 µm x 2 cm) 
and an analytical column (2 µm particles, 75 µm x 25 cm). Column compartment was held at 
40°C. Mobile phase of the nano pump consisted of 0.5% formic acid in H2O (component A) 
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and 0.5% formic acid in 50% ACN (component B). Mobile phase of the capillary pump 
consisted of 0.5% formic acid and 1% ACN in H2O (component C). The analytical column 
was equilibrated with 2% component B at a flow rate of 300nl/min. The preconcentration 
column was equilibrated with 100% component C. With a user defined injection routine 8 µl 
sample were stacked between loading solution (0.1% formic acid, 1% ACN in ultrapure water) 
in a 20µl sample loop. Sample loop was switched for 2 minutes in-line of the capillary pump 
flow to allow optimal trapping. Prior to the next injection sample the loop was washed with 
loading solution. After trapping the pre-concentration column was switched into the nano 
pump flow and component B was raised to 30% over 60 min, then to 95% over 5 min. After 
holding at 95% component B for 5 min the column was finally re-equilibrated at 2% 
component B for 15 min. Column outlet was connected to a UV detector with a 3nl flow-cell. 
4.2.2.12. ESI Mass Spectrometry 
The HPLC was directly coupled to a 3D ion trap ESI-MS (Bruker AmaZon). The ion trap was 
operated in Enhanced Resolution Mode with a capillary potential of 4 kV. The capillary 
temperature was set to 250 °C with a nebulizer pressure of 2 bar and a dry gas flow of 6 
l/min. MS² spectra were generated by use of the Auto MS² mode and Collision Induced 
Dissociation (CID).  
4.2.2.13. nanoESI Mass Spectrometry 
Outlet of the nanoLC was directly coupled to an ion trap ESI-MS (Bruker AmaZon) equipped 
with an on-line nano source (Bruker CaptiveSpray®). The ion trap was operated in Enhanced 
Resolution Mode with a capillary voltage of 1.7 kV. Source temperature was set to 200°C 
and a dry gas flow of 3 l/min was used to heat the source. 
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4.3. Results 
4.3.1. Development of the approach 
In order to achieve the goal of an analytical method for characterization of the 
pharmacokinetics of individual N-glycan variants of monoclonal antibodies an affinity 
purification approach had to be established which consumes only minute amounts of serum 
samples. In addition, the work-flow should be compatible with the existing biopharmaceutical 
development program as shown in Figure 1. The standard way is shown on the right utilizing 
immunoassays for the detection and quantification of proteins in (pre)clinical samples. On the 
left the glycan PK profiling work-flow is depicted schematically. The selected strategy was to 
purify the target protein and the N-glycans were released and labeled. Samples were then 
analyzed by LC-MS. All steps of the approach had to be optimized for the intended use and 
were subsequently qualified. 
 
Figure 1: Simplified work-flow of the (pre)clinical study analysis. Serum concentrations of the 
biopharmaceuticals are obtained by ELISA. Information about single glyco-variants is obtained by the 
work-flow shown on the left including affinity purification, glycan release and labeling and nanoLC-MS. 
Immunoassay analysis of (pre)clinical samples provides information about the absolute mAb 
content. All existing variants are quantified as a mixture providing that all variants can be 
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detected. In contrast LCMS based glycan PK profiling provides information about individual 
variants, in this case glyco-variants. However, the information is not quantitative; it is a 
differential analysis with a constant internal standard. Data from both arms can be combined 
and interpreted. 
Preclinical and clinical studies usually render a high number of samples. To be able to 
analyze large sets of samples a high-throughput affinity purification method with the use of 
96-well filter plates has been developed. High selectivity and sensitivity of affinity purification 
could be achieved using the binding partner or target protein of the protein of interest, in the 
case of monoclonal antibodies the antigen. First step for successful and efficient affinity 
purification was the immobilization of the antigen to a resin, e.g. sepharose with active 
groups. There were several commercially available sepharose resins, for protein 
immobilization two frequently used active groups are CNBr or NHS activated sepharose both 
binding to primary amines of the protein (e.g. lysine residues or the N-terminus). For the 
antigen immobilization NHS activated sepharose was optimal. The NHS group has an 
additional spacer arm to the resin which allowed a more efficient binding of mAbs because 
more potential binding sites were accessible. 5 µg of antigen was used for immobilization 
which enabled purification of approximately 14 µg of the appropriate mAb. 
After resin preparation, antigen immobilization and deactivation of remaining active group as 
described in the methods section the affinity plates could be used. First experiments were 
performed utilizing a vacuum device to force the liquid through the columns. However, 
inhomogeneous flow and contaminations from serum glycoproteins was observed resulting in 
poor reproducibility. Therefore, the work-flow was optimized using centrifugation which 
resulted in a highly reproducible procedure. 
 
4.3.2. Determination of the maximal mAb binding capacity of the affinity columns 
After implementation of the centrifugation work-flow, the coupling efficiency and maximal 
binding capacity of the affinity columns was determined. Coupling efficiency was evaluated 
analyzing three types of samples: (i) an aliquot of the antigen solution that was centrifuged 
into the column as reference, (ii) the direct flow through obtained after centrifuging the 
coupling solution into the sepharose column and (iii) the eluat after the first washing step 
collected after the coupling reaction which might contain uncoupled antigen. Figure 2A 
shows the resulting chromatograms of the direct flow through analysis from two replicates 
and the reference solution after C8 chromatography of the intact antigen. The sample 
contained 4 % and 10 % antigen respectively which was centrifuged through the column and 
not coupled to the resin. Variation between the samples was due to small differences of the 
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column volume. Coupling was subsequently optimized by adjusting the utilized volumes. 
Instead of 150 µl only 100 µl containing 5 µg of antigen were applied. Flow through was 
again analyzed after optimization and antigen could hardly be detected (Figure 2B). The flow 
through collected after the first washing step did not contain antigen also due to the high 
excess of free NHS groups compared to antigen that is used. 
 
 
Figure 2: UV chromatograms of antigen intact protein analysis. A) C8 chromatography. Results of 
coupling solution containing 0.033 mg mL-1 antigen and flow-through of two samples 1 and 2 are shown. 
B) SEC analysis. Results of coupling solution containing 0.05 mg mL-1 antigen and flow-through of two 
samples are shown after optimization of the work-flow. Injection volumes are depicted in inserts. 
 
4.3.3. Proof of concept study 
Next step was to test the developed affinity purification method for artificial serum samples. 
Serum samples were prepared by spiking a mAb into pooled rabbit serum. Dilutions were 
prepared to simulate concentrations of a typical preclinical study between 5 µg/ml and 85 
µg/ml (Figure 3). Bound mAb was washed several times and the glycosylated Fc parts were 
eluted enzymatically by centrifugation of Fabricator into the column and by incubation of the 
plates. N-glycans were released by PNGaseF, ultrafiltrated and labeled with 2-AA. The 
labeled N-glycans were then analyzed by LC-MS (method is described in detail in Chapter 2). 
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Figure 3: Exemplary PK profile of a mAb in a preclinical study obtained by ELISA. Dilution series was 
prepared according to concentrations obtained from the profile. 
 
However, the MS method was not sensitive enough to detect most of the 2-AA glycans. 
Consequently, detection and quantification was performed with the fluorescence detector of 
the HPLC. Results for four N-glycans with different percentages are shown in Figure 4. The 
results were in good agreement with the N-glycan composition obtained from 2-AA glycan 
maps of the mAb. 
For the MS analysis of all 2-AA N-glycans a more sensitive NanoLC-MS method was 
developed (see Chapter 3). Results of the nanoLCMS analysis are shown in Figure 5. All N-
glycans of the mAb were analyzed successfully. The percentages of G0F, G1F and M3G0F 
were identical to the fluorescence based quantification. The portion of M5 was smaller when 
using nanoLC-MS. This might be due to a slightly worse ionization efficiency of high 
mannose N-glycans. In addition, the variation between the samples was rather high due to 
small differences in the sample preparation and variation of the nanoLC-MS system lacking 
internal standards. In order to overcome this issue and to further improve the method an 
internal standard based on heavy isotopes was included into the work-flow. 
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Figure 4: Relative glycan composition of the proof of concept study obtained by fluorescence detection. 
 
 
 
 
Figure 5: Results of the proof of concept study. Spiked serum samples were analyzed by nanoLCMS after 
affinity purification and N-glycan processing. 
 
4.3.4. Differential analysis of N-glycans with heavy isotope 2-AA labeling 
Stable heavy isotope containing standards are frequently used for the quantitation of proteins 
or peptides by MS (16, 19). The standard can either be a peptide or an intact protein 
containing several 13C or 15N atoms. Due to the identical chemical properties the respective 
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standard has the same retention and ionization like the sample but the mass shift enables 
selective detection and quantification. Quantification or differential analysis of samples is 
performed against known or constant amounts of this standard. 
For N-glycans no stable heavy isotopes are commercially available and the production of 
multiple standards would be very expensive. The use of a stable heavy isotope containing 
label however is a viable and simple option to obtain stable heavy isotope variants for N-
glycan analysis. 13C 2-AA is commercially available with very high purity. A general drawback 
of using a 13C 2-AA labeled glycan standard is the rather late addition to the work-flow, at the 
earliest with PNGaseF after the affinity purification. This option reflects glycan release, 
labeling, purification and most important the nanoLC-MS analysis. Accordingly, the N-
glycans of the used mAb were released and labeled with the 13C 2-AA and used as the 
internal standard. This proceeding renders a standard for each N-glycan. 
 
Figure 6: MS raw spectrum of 2-AA labeled G2F glycan. The two isotopic pattern show the 2-AA labeled 
G2F (left) and the 6 Da heavier 13C 2-AA labeled G2F (right). The heavy isotope labeled N-glycan serves 
as internal standard for quantification. 
 
Figure 6 shows an exemplary profile spectrum of co-eluting 2-AA labeled G2F and its 
corresponding stable heavy isotope standard with six 13C atoms resulting in a mass shift of 
six Daltons. The intensity of the monoisotopic peak of the “light” sample relative to the 
intensity of the monoisotopic peak of the “heavy” standard was determined giving a “light” to 
“heavy” ratio (L/H). This ratio was determined for each N-glycan and time point of the 
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(pre)clinical study individually. Plotting the L/H ratio provided the PK profile for each N-glycan 
comparable to an ELISA profile. 
 
4.3.5. Comparison of mAb glycan map and results from affinity purification 
After implementation of the stable heavy isotope 2-AA glycan standard the resulting glycan 
map after affinity purification and N-glycan processing of mAb spiked samples (100 µg/ml) 
was compared to conventional glycan analysis of the mAb. The results are depicted in Figure 
7. The glycan map obtained from spiked serum samples showed some differences compared 
to the conventional glycan map. Some less abundant N-glycans with a portion below 0.1 % 
like the high mannose type structures M7 and M8 or hybrid type structures like one 
M5G1F/M6G0F and M4G1F/M5G0F isomer were not detected in the glycan maps of the 
serum samples. Two N-glycans were overrepresented in the serum samples. The 
percentages of the two bisecting N-glycans G1FB and G0FB were around ten times higher 
than in the drug product. The N-glycans appeared to be co-purified and were exclusively 
present when analyzing serum blanks. Additional washing steps (high and low pH, high NaCl 
or addition of soft detergent) did not lead to an improvement and these two glycans finally 
had to be excluded from analysis. High mannose glycan M5 percentages were smaller in the 
serum spiked samples. These results showed that there might be some glycan related 
impurities (e.g. from the two bi-secting glycans) which were co-purified with the target 
molecule. To prevent false results, negative and positive, quality control (QC) samples with 
varying mAb concentrations spiked into serum should be prepared in parallel to each 
analysis. Furthermore the results showed that N-glycans with very low abundance could not 
be analyzed with the developed method at preclinically relevant concentrations. 
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Figure 7: Comparison of relative glycan composition between drug product derived mAbs (grey) and 
serum spiked and affinity purified mAb (black). Magnified view and inset with full view are shown. 
 
4.3.6. Linearity of the N-glycan PK profiling method 
Linearity of the glycan PK method was determined including the complete work-flow with 
affinity purification, N-glycan processing and nanoLC-MS from repeated analysis of sample 
duplicates. Serial dilutions were prepared freshly and for each replicate individually. Serial 
dilutions contained nine relevant concentration levels (200, 100, 50, 25, 12.5, 6.3, 3.1, 1.6 
and 0.8 µg/ml). The L/H ratio was determined for each N-glycan and normalized relative to 
the signal at 200 µg/ml. These relative L/H ratios were plotted against the respective 
concentration and under the assumption of linear correlation a linear regression was 
performed. Table 1 lists the linear range of each N-glycan of the mAb. Previously excluded 
G1FB and G0FB as well as the not detectable high mannose and hybrid structures are not 
shown. Linearity was given for regressions with R² > 0.980. 
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Table 1: Linearity of the developed glycan PK profiling method. Linearity was determined for each N-
glycan. Linear range with LLOQ, ULOQ and coefficient of determination is depicted. 
 
Linear range [µg/mL] Linear correlation 
N-glycan LLOQ ULOQ R² 
M6 3.1 100.0 0.996 
M5 0.8 100.0 0.991 
G0 1.6 100.0 0.984 
M3 3.1 200.0 0.986 
M5G1F/M6G0F 25.0 100.0 0.979 
G2F 0.8 200.0 0.985 
M5G1F/M6G0F 12.5 100.0 0.971 
G1F 0.8 100.0 0.992 
M3G1F 0.8 100.0 0.988 
M3G0F 1.6 100.0 0.995 
G0F 0.8 100.0 0.992 
 
The lower limit of quantification (LLOQ) which is the lowest concentration still fitting to linear 
regression of major N-glycans was lower than for minor abundant N-glycans. G0F, G1F, M5 
and G2F signals were linear to 0.8 µg/ml. To obtain valid glycan maps including all N-glycans 
the mAb concentration must be as high as the lowest LLOQ. In the present case 25 µg/ml. 
However the portion of the two M5G1F/M6G0F isomers was around 0.1 – 0.2 % of the total 
mAb glycan content and thus the potential influence on PK would be limited. The remaining 
nine N-glycans of the mAb were analyzed between 100 µg/ml and 3.1 µg/ml. Immobilization 
of 5 µg antigen per affinity column was sufficient to theoretically purify 14 µg mAb or when 
using a serum sample volume of 50 µl a mAb concentration of 280 µg/ml. In practice the 
maximal binding capacity should be lower due to a coupling efficiency <100% and saturation 
effects during the binding step. The observed maximal binding capacity within the linear 
range of ~5µg mAb (100 µg/ml when using 50 µl sample volume) was therefore in good 
agreement with the expected values. 
In Figure 8 linearity plots of all eleven investigated N-glycans are shown. Relative L/H ratio 
was plotted against protein concentration. The straight line resulting from linear regression is 
depicted in each diagram. 
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Figure 8: Linearity plots of the eleven N-glycans of the mAb that could be analyzed with the developed 
method. 
 
4.3.7. Tracking increasing degalactosylation with the N-glycan PK profiling 
method 
To further qualify the method an artificial change of the N-glycosylation composition was 
prepared by admixing increasing amounts of degalactosylated mAb to normal glycosylated 
mAb. The samples were analyzed with the PK profiling method to determine if the change 
can be observed as well as the minimal change that can be detected. The portions of normal 
and degalactosylated mAb are listed in Table 2 for each sample. Experiment 1 was the 
control experiment with eight samples containing only normal mAb. In experiment 2 the 
portion of degalactosylated mAb was increased to 100%. In experiment 3 and experiment 4 
the portion of degalactosylated mAb was increased to 20 % and 5 % respectively. The total 
mAb concentration was constant at 100 µg/ml. 
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Table 2: Experimental set-up of the degalactosylation experiment. Four different dilution series were 
prepared. 
 Experiment 1 Experiment 2 Experiment 3 Experiment 4 
# 
Deglactosylated 
mAb 
normal 
mAb 
Deglactosylated 
mAb 
normal 
mAb 
Deglactosylated 
mAb 
normal 
mAb 
Deglactosylated 
mAb 
normal 
mAb 
1 0,00% 100,00% 0,00% 100,00% 0,00% 100,00% 0,00% 100,00% 
2 0,00% 100,00% 10,00% 90,00% 2,50% 97,50% 0,63% 99,38% 
3 0,00% 100,00% 20,00% 80,00% 5,00% 95,00% 1.30% 98,75% 
4 0,00% 100,00% 30,00% 70,00% 7,50% 92,50% 1.88% 98,12% 
5 0,00% 100,00% 50,00% 50,00% 10,00% 90,00% 2.50% 97,50% 
6 0,00% 100,00% 70,00% 30,00% 12,50% 87,50% 3.75% 96,25% 
7 0,00% 100,00% 90,00% 10,00% 15,00% 85,00% 4.38% 95,63% 
8 0,00% 100,00% 100,00% 0,00% 20,00% 80,00% 5.00% 95,00% 
 
Percentages of terminal galactosylation resulting from summing-up the portions of G2F, G1F 
and M3G1F for the eight samples of each experiment are shown in Figure 9. The control 
experiment had a constant portion of approximately 18 %. Experiment 2 showed a constant 
decrease of terminal galactosylation. A small amount of terminal galactosylation remained in 
the last sample indicating incomplete degalactosylation. 
Experiment 3 showed a decrease from 17.7 % galactosylation to approximately 15 % which 
was a shift of 15 % relative to the initial portion. Considering an incomplete degalactosylation 
as seen for experiment 2 this result demonstrated that a relative change of 20 % or 15 % 
terminal galactosylation can be detected. In experiment 4 with a theoretical change of 5 % a 
2.5 % change was observed, but the samples could not be differentiated from the control 
sample. Thus the decrease of individual N-glycans should be at least 10 – 15 % (relative to 
initial portion) in order to be detected with the developed approach. 
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Figure 9: Galactosylation levels of experiment 1 (diamond), experiment 2 (square), experiment 3 (triangle) 
and experiment 4 (cross). Dashed line in the same color indicate the theoretical values. 
As a consequence of the decrease in terminal galactose residues an increase of terminal N-
acetylglucosamine should be detectable. Terminal GlcNAc was determined by summing-up 
the percentages of G0F and M3G0F which were also produced by enzymatic removal of 
galactose residues from G1F, G2F and M3G1F. The results were similar to the quantification 
of terminal galactosylation (Figure 10). For experiment 2 and 3 the increase of terminal 
GlcNAc was slightly higher than calculated. Samples from experiment 4 could not be 
distinguished from the control experiment samples. Thus the developed method was suitable 
to detect changes with a relative change of at least 10-20% of single N-glycans. 
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Figure 10: Terminal GlcNAc levels after enzymatic degalactosylation. Experiment 1 (diamond), experiment 
2 (square), experiment 3 (triangle) and experiment 4 (cross). Dashed lines in the same color indicate the 
theoretical values. 
 
 
4.3.8. Robustness of the N-glycan PK profiling method 
The final experiment to qualify the N-glycan PK profiling method was a robustness 
experiment. Two different operators performed the complete work-flow including affinity 
purification, nanoLC-MS and data interpretation without sharing any reagents. Resulting 
glycan maps are shown in Figure 11A and B. Error bars show the standard deviation 
determined from full replicates. The results of the two operators were in very good 
agreement. For example most abundant G0F was 75.9+/-0.3% for operator A and 74.9%+/-
0.8% for operator B and for the low abundant core structure M3 percentages were 0.54+/-
0.06% and 0.63+/-0.07% for operator A and B respectively. The standard deviation was 
smaller than 1% for all glycans with overlapping error bars. These results demonstrated the 
robustness of the developed approach. 
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Figure 11: Robustness of the N-glycan PK profiling method. Results of glycan PK profiling of spiked 
samples performed by two different operators (A). Magnified view to show minor abundant N-glycans (B) 
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4.4. Conclusion 
 
In this chapter the development of a glycan PK profiling approach with high-throughput 96-
well plate based sample preparation is described in detail. Different development steps from 
the preparation of affinity columns and optimization of antigen coupling to the NHS resin to 
the implementation of stable heavy isotope 2-AA glycan standards are pictured. Furthermore 
the qualification of the method is shown which encompasses a proof of concept study 
demonstrating the general suitability to analyze N-glycans from serum samples, the 
determination of linearity, robustness experiments and a second study simulating a decrease 
of terminal galactose residues. 
The results demonstrate that N-glycan PK profiling can be performed using only 50 µl of 
serum samples with linearity between 3 µg/ml and 100 µg/ml for N-glycans with a portion of 
0.5%. With the developed method it is possible to detect relative changes of approx. 10 – 
15 % of individual N-glycans which was demonstrated with the spiking of degalactosylated 
mAb and the method can be performed by different operators with minimal variation of the 
results which allows routine use. Analysis of major N-glycans is possible from 50 µl serum 
samples at concentrations below 1 µg/ml. 
Summarizing, the development was successful resulting in a method a sensitivity which has 
not been previously described in the literature. The minimal sample consumption allows 
implementation into the existing (pre)clinical development work-flow and no additional 
studies have to be performed.  
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Chapter 5 
 
Influence of glyco-variants on the pharmacokinetics 
of an IgG1 biopharmaceutical 
 
This chapter is intended for publication. 
 
Abstract 
N-glycosylation as the most complex post translational modification can impact safety and 
efficacy of biopharmaceuticals. Possible effects on the pharmacokinetics caused by glyco-
variants have been subject of several studies with in part contradictory results which can be 
related to differences in the set-up. In this study a work-flow is presented that allows the 
analysis of a possible influence of individual glyco-variants on the PK. Prerequisite of 
individual glycan PK analysis was a reference standard based on stable heavy isotope 
labeled glycans. The high sensitivity and low sample consumption enabled the integration 
into the preclinical and clinical development program of a biopharmaceutical. Analysis of 
samples from a preclinical rabbit study demonstrated the feasibility of the approach. The data 
of an IgG1 biopharmaceutical showed that some N-glycans have a different PK profile 
compared with the average molecule as determined by ELISA. IgG1 high mannose glycans 
M5 and M6 were removed from circulation at a higher rate by two different mechanisms. First 
M6 was converted to M5 in circulation by glycosidases and thereby completely removed. 
Second M5 glycosylated IgG1 was selectively removed by the mannose receptor. It was 
concluded with data from intact antibody resolving the major glycoforms that the observed 
incomplete removal of M5 was because of the favored M5:M5 pairing on the IgG1 and the 
resulting structural changes of the Fc part caused by the size of the glycoforms. This change 
made the N-glycans accessible for the mannose receptor to bind and selectively removed 
the glycoform containing IgG. 
Keywords: monoclonal antibody, N-glycosylation, pharmacokinetics, mass spectrometry, 
heavy isotope standard 
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5.1 Introduction 
N-glycosylation, one of the most complex post-translational modifications is under suspicion 
to influence the pharmacokinetics of therapeutic proteins. One class of therapeutic proteins, 
mAbs that carry one N-glycan per heavy chain at their Fc part were subject of several studies 
(1–3). Newkirk et al generated degalactosylated IgG1 and IgG2 and showed that the 
degalactosylated mAb was cleared at a slower rate in mice (4). In another study an IgG 
enriched in high mannose glycostructures was compared to complex glycosylated IgG. No 
difference in PK was found by ELISA. Fab glycosylation was investigated too via enrichment 
of an IgG to contain one N-glycosylation in its variable domain. However no influence on PK 
was observed (5). 
The major drawback of enrichment experiments is the generation of an artificial new IgG N-
glycoform pattern that does not necessarily give the same results as the individual 
glycoforms in the original IgG. LC-MS based approaches allow the direct analysis of the N-
glycosylation from the heterogenic mAb N-glycoform mixture. Using a LC-MS method an 
increasing clearance of high mannose N-glycans was reported by several groups (6–10). 
With a single subject case study Chen et al. were the first to describe a conversion of high 
mannose glycans M6-M9 to M5 on an IgG2 which occurred in the blood stream due to 
circulating glycosidases (6). The same group demonstrated for an IgG1 an increased 
clearance of M5 glycoforms in addition to this conversion (7). Alessandri et al. reported a 
conversion of M6 and M7 to M5 in circulation in vitro and increased in vivo clearance of the 
high mannose glycans compared to complex structures, however the significance of the in 
vivo data of M6 and M7 is questionable (9). Using mAbs exclusively glycosylated with M9 
and M8 or M5, studies were performed in mice showing that M8/9 and M5 IgGs were cleared 
much faster compared to complex glycosylated IgGs and that M8/9 glycans were in vivo 
converted to M6 (8). It was concluded that these faster cleared N-glycans bound to N-glycan 
specific receptors and were subsequently removed via endocytosis (11–13). Correspondingly, 
the mannose specific receptor was thought to bind terminal mannose residues resulting in 
fast clearance of high mannose structures (14–17). In contrast to the immunoassay and 
studies with enriched IgG fractions the results obtained with LC-MS methods from the human 
case studies are in good agreement. However, the studies have some drawbacks as e.g. the 
number of subjects is small and does not allow for statistically significant conclusions, the in 
vitro data are significant but the in vivo results or the serum sample volumes do prevent the 
use of the study setup N-glycan PK profiling as an accompanying analysis to clinical studies. 
The most important drawback is that clinical studies are performed late from a development 
perspective and an adjustment of the mAb N-glycosylation based on the findings from the N-
glycan PK profiling is hardly possible at this development stage. Therefore it would be 
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advantageous if the influence of N-glycans could be studied earlier, e.g. already during the 
preclinical phase to be able to optimize the biopharmaceutical, for example by glyco-
engineering. This requires that effects observed in human studies like the increased 
clearance of high mannose glycans must be identical in animals used in preclinical 
development (e.g. rabbits or monkeys). Furthermore, serum sample consumption must be 
minimal and the sensitivity of the LC-MS methods must be increased drastically as serum 
volume is more limited in animal studies. Finally, the throughput of the methods must be 
increased to analyze a statistically powerful number of animals. 
In this study a possible approach circumventing the mentioned limitations is presented. The 
method comprises a high-throughput sample preparation procedure encompassing affinity 
purification using immobilized antigen and glycan processing. The work-flow was completely 
based on 96-well plate format. Analysis of 2-AA labeled N-glycans was performed with a 
highly sensitive nanoLCMS using reversed phase chromatography which was previously 
shown to be robust and sensitive (18). Quantification by MS was achieved using a stable 
heavy isotope 2-AA label that contains six 13C atoms (22). The use of this internal standard 
compensated for variations in the sample preparation and resulted in a higher precision of 
the nanoLCMS analysis. Together with the small scale sample preparation N-glycan PK data 
were obtained from 50 µl serum samples from an IgG1 s.c. PK study performed in rabbits. 
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5.2 Materials and Methods 
5.2.1 Materials 
2-Aminobenzoic acid, ethanolamine, formic acid, picoline borane, DMSO, 13C aminobenzoic 
acid were from Sigma (Munich, Germany). PNGaseF was from Roche (Penzberg, Germany). 
Acetic acid, acetonitrile and hydrochloric acid were from Merck (Darmstadt, Germany). NHS 
activated sepharose, Sephadex® G-10 96-well plates and 96-well deep well plates were from 
GE Healthcare (Munich, Germany). Antigen was from Peprotech (Hamburg, Germany). 
Phosphate buffered saline was from Gibco/Life technologies (Darmstadt, Germany). 
Multicreen THS HV filter plates were from Milipore. Fabricator was Genovis (Lund, Sweden). 
96-well plates were from Nunc/Thermo Scientific (Munich, Germany). AcroPrep™ Advance 
Omega™ 10K 96-well filter plates were from Pall (Dreieich, Germany). Pre-clinical rabbit 
serum samples were obtained from clinical bioanalytics at Sandoz. 
 
5.2.2 Methods 
5.2.2.1 Preclinical rabbit study 
The preclinical study was performed in New Zealand White rabbits. Following single 
subcutaneous administration of 10 mg kg-1 b.w. of an IgG1 blood samples were drawn over 
29 days including one pre-dose blood sample. Detailed sampling is listed in Table 1. 
Concentration of mAb2 in serum was determined by ELISA. From remaining serum 2 x 50 µl 
aliquots were used for glycan PK profiling. The first aliquot was analyzed and the second 
aliquot served as back-up aliquot. mAb concentration in pre-clinical serum samples was 
determined using a sandwich ELISA. Free mAb2 was quantitatively analyzed using 
immobilized antigen and a horse radish peroxidase conjugated probe specifically binding 
mAb2 for detection. 
5.2.2.2 Reconstitution of the antigen 
Recombinant human antigen was reconstituted according to the manufacturer instructions. 
Antigen was dissolved in H2O (1 mg/mL) and reconstituted for 2 hours at room temperature. 
Reconstituted antigen was diluted (0.5 mg/ml) with H2O and stored at -20°C until use. Prior to 
immobilization the antigen was diluted with PBS (0.05 mg/ml). 
5.2.2.3 Preparation of 13C 2-AA labeled glycan standard 
N-glycans of desalted mAb (1 mg) were released using PNGaseF overnight (17 h) at 37°C. 
The N-glycans were separated from the proteins by use of Amicon 30K filter devices and 
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were brought to dryness (Speedvac). Picoline borane and [13C] 2-AA were dissolved in 70:30 
(% v/v) DMSO-acetic acid to furnish labeling solutions of 63 and 50 mg mL-1, respectively. 
Labeling solution (15 µL) and deionized water (10 µL) were added to 15 nmol glycans. The 
labeling reaction was performed at 37°C for 17 h. Excess label was removed by gel filtration 
on G-10 columns. Columns were conditioned with 10ml H2O. Samples were diluted to 100 µl 
with deionized H2O before application to the column. After rinsing the column with 700 µl H2O 
the purified fluorescence labeled N-glycans were eluted with 600 µl H2O. Purified [13C] 2-AA 
labeled N-glycans (25 pmol/µl) were aliquoted and stored at -20°C until use. 
5.2.2.4 Preparation of 96-well plate affinity columns with immobilized antigen 
The membranes of a 96 well filter plate were wetted with 1 mM HCl (100 µL) before addition 
of 200 µL NHS activated sepharose-isopropanol slurry per well. Isopropanol was removed by 
centrifugation and the columns were washed with 1 mM HCl (150 µL) for four times. Antigen 
solution (100 µL) was centrifuged into the columns and coupling reaction was allowed to take 
place for 2 hours at ambient temperature. Affinity columns were washed and remaining NHS 
groups were inactivated using of ethanolamine buffer (150 µL). Finally columns were 
equilibrated with PBS. 
5.2.2.5 Affinity purification of an IgG1 biopharmaceutical and glycan release 
Serum samples (50 µL) were diluted to 100 µL with PBS and applied to the affinity 
purification column by centrifugation. Bound mAb was washed several times with PBS to 
remove serum and unspecific bound proteins. Fabricator® solution was centrifuged into the 
columns to release the glycosylated Fc part of the mAb. Reaction was performed at 37°C for 
30 minutes. Released Fc parts were eluted with PBS and PNGaseF with 13C-2-AA labeled N-
glycan standards was added. This mixture was incubated for 17 hours at 37°C. Remaining 
proteins were removed by ultrafiltration using 96-well plates with 10K cut-off membranes. 
Released N-glycans with glycan standard were dried by vacuum centrifugation. 
5.2.2.6 N-glycan labeling 
Dried samples containing free reducing end N-glycans and 13C 2-AA labeled glycan 
standard were dissolved in H2O (10 µL) and 2-AA labeling solution (15 µL; 100 mg/mL 
picoline borane, 50 mg/mL 2-AA in a 7:3 mixture of DMSO and acetic acid) was added. 
Labeling reaction took place for 17 hours at 37°C. 
 
 
 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 5 
104 
 
5.2.2.7 Gel filtration 
Custom made 96-well plate Sephadex G-10 columns were equilibrated with 800 µL H2O. 
Labeled samples were filled up to 100 µL with H2O and applied to the gel filtration columns. 
2-AA and 13C 2-AA labeled N-glycans were eluted with 150 µl H2O. Finally samples were 
brought to dryness by vacuum centrifugation and were redissolved in 20 µL H2O for nanoLC-
MS analysis. 
5.2.2.8 NanoLC of labeled N-glycans 
NanoLC (Thermo/Dionex Ultimate 3000) was set-up in “preconcentration” mode according to 
the manufacturer manual with a pre-concentration column (3 µm particles, 75 µm x 2 cm) 
and an analytical column (2 µm particles, 75 µm x 25 cm). The column compartment was 
held at 40°C. The mobile phase of the nano pump consisted of 0.5% formic acid in H2O 
(component A) and 0.5% formic acid in 50% ACN (component B). Mobile phase of the 
capillary pump consisted of 0.5% formic acid and 1% ACN in H2O (component C). The 
analytical column was equilibrated with 2% component B at a flow rate of 300 nl/min. The 
preconcentration column was equilibrated with 100% component C. With a user defined 
injection routine 8 µl sample were stacked between loading solution (0.1% formic acid, 1% 
ACN in ultrapure water) in a 20 µl sample loop. Sample loop was switched for 2 minutes in-
line of the capillary pump flow to allow optimal trapping. Prior to the next injection sample the 
loop was washed with loading solution. After trapping the pre-concentration column was 
switched into the nano pump flow and component B was raised to 30% over 60 minutes, 
then to 95% over 5 minutes. After holding at 95% component B for 5 minutes the column was 
finally re-equilibrated at 2% component B for 15 minutes. Column outlet was connected to a 
UV detector with a 3 nl flow-cell. 
5.2.2.9 Mass Spectrometry 
The outlet of the nanoLC was directly coupled to an ion trap ESI-MS (Bruker AmaZon) 
equipped with an on-line nano source (Bruker CaptiveSpray®). The ion trap was operated in 
Enhanced Resolution Mode with a capillary voltage of 1.7 kV. Source temperature was set to 
200°C and a dry gas flow of 3 l/min was used to heat the source.  
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5.3 Results and discussion 
5.3.1 Preclinical study and ELISA 
The preclinical study was performed in New Zealand White Rabbits. 15 animals were 
included in this study. A single subcutaneous dose of an IgG1 biopharmaceutical (mAb2) 
with 10 mg per kg body weight was administered. Serum samples were taken at 12 time 
points after administration. Details to the sampling are listed in Table 1. Concentration levels 
of mAb2 were determined by ELISA. The mean PK profile of all variants and glycoform as 
determined by ELISA is shown in Figure 1. Remaining serum samples were used for N-
glycan PK profiling. 
 
Table 1: Sampling schedule of the pre-clinical study of an IgG1. At each sampling time point ~500 µl of 
serum were drawn. 
Day 1 1 1 2 2 3 3 4 5 8 15 22 29 
Hours  
[post-dose] 
0 
(pre-dose) 
2 8 24 40 48 60 72 96 168 336 504 672 
 
 
Figure 1: ELISA results with standard deviation from 15 rabbits that were included in the preclinical study 
of an IgG1 biopharmaceutical. 
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5.3.2 Affinity purification and N-glycan processing 
Glycoforms can only be studied on the intact protein level usually limited to the major 
glycoforms due to the relative distribution of N-glycans. For glycan PK profiling N-glycans are 
studied instead which can be performed with more sensitivity. A high throughput affinity 
purification method based on 96 well plates was previously developed. Detailed development 
and qualification of the method were described in Chapter 4. 
 
Figure 2: Glycan PK work-flow. 1. Serum samples are applied to 96-well based affinity purification 
columns with immobilized antigen (light green). 2. The column is extensively washed. 3. The N-glycan 
containing Fc part is released by centrifugation of Fabricator enzyme into the column and incubation at 
37°C for 30 minutes. Fab and unspecific bound proteins remain on the column. 4. PNGaseF and heavy 
isotope standard (
13
C 2-AA N-glycans) are added to the Fc part. Incubation for 17 h at 37°C. 5. Released 
sample N-glycans and heavy isotope standard are purified from proteins by ultrafiltration. 6. 2-AA labeling 
of sample glycans and subsequent gelfiltration to remove excess label. 7. NanoLC-MS analysis. 
 
In brief the workflow was as followed: Affinity columns were prepared as described in the 
methods section. Sepharose columns with NHS groups were prepared in 96 well filter plates. 
5 µg antigen of mAb2 per well were immobilized by coupling to the NHS groups. Remaining 
free NHS groups were deactivated by washing of affinity columns with ethanolamine buffer. 
Columns were finally equilibrated with PBS. Recovery of mAb2 from rabbit serum is 
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schematically shown in Figure 2. mAb containing serum samples were applied to the 
sepharose columns with the immobilized antigen. The samples were centrifuged through the 
column and the column was washed several times to remove unspecific bound proteins. 
Affinity purification with the respective antigen has the advantage of very high affinity and 
specificity due to the strong interaction of mAbs with their antigen. However, one major 
drawback is the limited recovery of mAbs after acidic elution. With the limited sample volume 
available an alternative to the acidic elution with higher yield had to be established which is 
described in the following paragraph: 
On-column deglycosylation as described in chapter 3 could not be used because of 
endogenous serum glycoproteins that were bound unspecific to the sepharose resin and 
could not be removed by additional washing steps. With only one N-glycosylation site at the 
Fc part mAbs are suitable for an enzymatically elution step. The enzyme IdeS selectively 
cleaves IgG heavy chains C-terminal of the disulfide connection thereby releasing the two 
glycosylated heavy chain fragments that can subsequently be deglycosylated with high 
efficiency. Deglycosylation was performed by use of PNGaseF. Together with PNGaseF a 
stable heavy isotope standard was added to the samples. 13C 2-AA labeled N-glycans 
obtained from mAb2 was used as the internal standard. Released N-glycans were labeled 
with 2-AA. Excess label was subsequently removed by gelfiltration. Labeled sample N-
glycans and the heavy isotope standard were analyzed by RP nanoLC-MS. 
Data interpretation was done by determining the peak area of the respective light sample 
glycan and its appropriate heavy isotope standard from their EICs. This light to heavy ratio 
(L/H) was determined for each N-glycan at each time point and animal. By plotting the L/H 
ratio against time PK profiles for each N-glycan are obtained. The N-glycan percentages 
were calculated with the known relative distribution of heavy isotope standard glycans for 
each sampling time point. 
 
5.3.3 mAb2 N-glycosylation and qualification of the study 
To qualify and control the affinity purification quality check samples were prepared by spiking 
known amounts of mAb2 into NZW rabbit serum. The quality check samples covered the 
concentration range of the study which was previously determined by ELISA. Figure 3 shows 
the mean percentages of the 1, 10 and 100 µg/ml mAb2 quality check samples. The mean 
percentages of the glycans obtained from the quality check samples represented the mAb2 
N-glycan composition. With the developed enzymatic elution of the glycosylated antibody 
fragments very high selectivity and purity was achieved. No interfering N-glycans of mAb2 
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were co-purified with the exception of two minor abundant bisecting variants that were 
excluded from analysis. No additional serum related N-glycans were detected. Sensitivity 
was sufficient to analyze all N-glycans with a percentage of at least 0.1 % at a concentration 
of 10 µg/ml. 
 
Figure 3: (A) Average glycan map obtained from 10 and 100 µg/ml quality check samples shows the 
relative N-glycan composition. (B) Magnified view shows the minor abundant N-glycans. Error bars show 
the standard deviation of the method. 
 
The N-glycans were mainly complex biantennary with core fucose. The most abundant N-
glycan was G0F (65 %) with terminal N-acetylglucosamine residues followed by G1F (16 %) 
with one additional terminal galactose. High mannose glycan M5 (9.5 %) was the third most 
abundant N-glycan. All other N-glycans had a portion of less than 3%. mAb2 contained no N-
glycans with terminal sialic acids. Glycan structures are shown in Figure 4. 
 
Figure 4: N-glycan structures of mAb2. Blue square stands for N-Acetylglucosamine, green circle for 
mannose, yellow circle for galactose and red triangle for fucose. 
 
5.3.4 Glycan PK profiles of mAb2 
The determined glycan L/H ratios were plotted against the sampling time to obtain PK 
profiles for each N-glycan. Mean L/H ratios for each N-glycan were normalized to the 
maximum of each N-glycan L/H curve (Figure 5). ELISA data were normalized in the same 
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way. The PK profile of the most abundant complex type G0F was very similar to the ELISA 
profile (Figure 5A). The maximum concentration (tmax) was reached after 72 h with 
congruency of the ELISA and the L/H graph. Elimination occured at identical rates and the 
PK profiles were regarded as comparable. This finding was expected for the major N-glycan 
contributing 70 % of the total mAb2 as the ELISA represents the average profile of all 
glycoforms which is dominated by G0F. The second most abundant complex type N-glycan 
G1F that accounted for approximately 16 % also showed a PK profile which was very similar 
compared to the ELISA profile (Figure 5B). Again tmax was reached at 72 h. Complex type 
G2F with a portion of 2 % had the best match with the ELISA profile showing almost perfect 
congruency (Figure 5C). The tmax was reached one sampling time point earlier after 60, but 
the two profiles could still be regarded identical. The profile of the M6G0F/M5G1F hybrid type 
glycan represented two isomers that could not be differentiated with the nanoLC-MS 
approach and which had a relative content of only 0.1 %. The profile and tmax were similar to 
the ELISA profile as well (Figure 5D). The low abundance brought the analysis close to the 
LLOQ which resulted in lower precision and higher variation. The glycan PK profiles of M3, 
M3G0F and M3G1F were also highly similar to the ELISA profile (Figure 5E, F, G). These 
results demonstrated that PK profiles could be obtained for each N-glycan individually. The 
glycan PK profiles were highly similar to the ELISA for the most abundant glycans. For N-
glycans with a portion smaller than 0.5 % the graphs showed higher variation. 
Considering all the glycan forms analyzed, only the high mannose type N-glycans M5 and 
M6 with 9.5 % and 2 % relative abundance respectively showed a clear discrepancy from the 
ELISA profile (Figure 6) The maximum concentration of M6 was reached after 24 h followed 
by either a conversion to M5 or an increased elimination rate that led to a faster clearance to 
a level below the LLOD or a complete removal from circulation at the 168 h time point. The 
high mannose glycan M5 profile also differed from the overall mAb ELISA PK profile (Figure 
6B). The tmax was reached 24 h earlier already after 48 h and these molecules were cleared 
faster between 48 h and 168 h. 
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Figure 5: Comparison of nanoLC-MS based glycan PK data and ELISA data for G0F (A), G1F (B), G2F (C), 
M5G1F/M6G0F (D), M3 (E), M3G1F (F), M3G0F (G). Concentration is relative to the maximum of each curve 
to enable comparison. Mean profiles from 15 animals are shown. 
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Figure 6: Comparison of high mannose glycan M6 (A) and M5 (B) PK profiles obtained by nanoLC-MS 
(diamond) and ELISA (squares) profiles. 
 
5.3.5 Selective clearance of M5 and M6 
As shown above high mannose glycan PK profiles differed from the ELISA profile of mAb2 
which represented the average concentration of all protein variants. The findings should be 
reflected in the glycan maps at each time point (Figure 7). PK profiles for G0 could not be 
obtained due to co-elution of a contaminant with the same m/z value. Glycan maps could be 
calculated for time points between 8 h and 336 h. At 2 h, 504 h and 672 h the mAb2 serum 
concentration was below the LLOQ of 10 µg/ml for many rabbits. 
 
Figure 7: Glycan Maps of mAb2 for each time point. Mean percentage of recovered mAb2 N-glycans after 
single subcutaneous administration in rabbits. Full view (A) and magnified view (B) are shown. 
 
Mean percentages of the most abundant N-glycans G0F and G1F stayed constant which 
confirmed the previously made observations based on the glycan PK profiles (Figure 7). The 
magnified view demonstrates that the contribution of all N-glycans was constant except for 
the high mannose glycans M5 and M6 portions which decreased over time. M6 was removed 
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from circulation below the LLOQ or completely within 168h whereas the M5 portion 
decreased from the initial percentage of 9 % to approximately 4 % after 336 h. 
High mannose species M6-M9 were converted by glycosidases in circulation to the smaller 
high mannose glycans M5 in humans (6, 9). In mice a similar observation was made as high 
mannose species M7-M9 were converted to M6 (8). Both observations were made with in 
vitro incubation of antibody in serum. In the present rabbit study M5 was removed selectively 
from circulation. An increase of smaller glycans like M4 (not present in mAb2) or M3 (core 
structure) was not observed. A further conversion of M5 would require additional enzymes 
with other specificities in serum because the linkage of the terminal mannose residues of M5 
is different to that of M6-M9. Removal of mannose residues from M6-M9 requires cleavage of 
α 1,2 glycosidic bonds whereas M5 terminal mannose residues are connected via α 1,3 and 
α 1,6 glycosidic bonds. It is very likely that M5 and in conclusion M5 containing glycoforms 
are removed by a specific clearance mechanism from circulation involving the mannose 
receptor. 
Table 2: Portions of glycoforms containing M5. Theoretical values were calculated based on the 
assumption of random pairing. 
 
M5:M5 M5:G1F M5:M3G1F M5:G0F M5:M3G0F G0F:G0F 
Calculated 
relative 
0.62% 1.12% 0.11% 5.29% 0.18% 45.43% 
Calculated 
relative to the 
most abundant 
G0F:G0F 
1.36% 2.46% 0.24% 11.64% 0.40% 100% 
Observed 
relative to the 
most abundant 
G0F:G0F 
5.13% - - 12.73% - 100% 
 
The incomplete removal of M5 from circulation observed in this study could be explained by 
the structural conformation of the Fc part. Several investigations showed that IgGs exhibiting 
N-glycans with terminal galactosylation on both heavy chains change the conformation of the 
Fc part to a horseshoe conformation which makes the N-glycans accessible for receptors 
(23). Compared to M5 these galactosylated N-glycans (e.g. G1F or G2F) have a similar size. 
This implies that glycoforms containing M5 and a second N-glycan of similar size (e.g. M5, 
G1F or G2F) could be large enough to force the Fc part into an open conformation. The 
mannose receptor is then able to bind M5 and remove the IgG from circulation. 
It was shown that the assembly of the glycosylated heavy chains during protein biosynthesis 
in the ER is not random (24). For an IgG2 biopharmaceutical it was demonstrated that the 
glycoform M5:M5 is favored (7). For mAb2 in the present study similar observations were 
made (Table 2). Assuming random pairing all theoretical glycoforms percentages can be 
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calculated which is shown in Table 2 for M5 containing glycoforms. MS data from intact 
mAb2 showed that the M5:M5 glycoform content was four times higher than the theoretically 
value assuming random heavy chain assembly. M5:M5 was strongly favored during protein 
biosynthesis and as mentioned above it is likely that mAb2 Fc part with this glycoform has a 
horseshoe conformation which in turn results in an increased clearance from circulation by 
binding to the Mannose receptor. The remaining 4 % M5 observed in the preclinical study 
were M5:G0F and other glycoforms that are small enough for a closed Fc conformation. 
Other glycoforms with an open Fc part would be M5:G1F or M5:G2F, however analysis of 
these glycoforms was not possible for mAb2 because of the major glycoforms overlaying the 
M5:G1F and M5:G2F glycoforms in the intact mass spectrum. Thus, the incomplete 
clearance of M5 glycoforms from circulation could be explained by the glycan pairing and the 
corresponding effect on Fc structure. 
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5.4 Conclusion 
An innovative approach for the investigation of individual N-glycan pharmacokinetics was 
utilized to analyze a preclinical rabbit study of an IgG1 biopharmaceutical. Using 96 well 
plate based high throughput affinity purification with immobilized antigen and stable heavy 
isotope standard nanoLC-MS quantification glycan PK data from only 50 µl serum samples 
was obtained for mAb concentrations between 10 and 90 µg/ml. A rabbit study including 15 
animals was successfully analyzed and demonstrated the feasibility of the developed 
approach as an accompanying method in preclinical development. PK profiles for individual 
N-glycans were obtained which was so far not described in literature. These glycan PK 
profiles were compared to ELISA data demonstrating that high mannose glycans M5 and M6 
had a different PK profile. Glycan maps showed that M6 was either removed below the 
LLOQ or was completely removed during the first 48 h and M5 levels decreased from 9.5 % 
to approximately 4 %. 
The results are similar to data from human case studies. This demonstrates the value of 
glycan PK profiling with preclinical samples. The observed decrease of glycoforms containing 
high mannose glycans M5 and M6 can be explained by two mechanisms. The decrease of 
M6 is due to conversion to M5 by specific glycosidases present in serum and has been 
reported for several species (6, 8, 9). However, this conversion mechanism is not applicable 
for the M5 decrease because of the enzyme specificity. This is in agreement with the 
observation of constant M3 and no detection of M4 glycoforms in the study. M5 decrease can 
be explained by a second mechanism. Glycoforms containing M5 are selectively cleared 
from circulation through receptor mediated endocytosis. The responsible mannose receptor 
binds among others specific to mannose containing glycoproteins and removes them from 
circulation (11, 12, 14, 16, 17). The M5 glycoforms do not disappear completely but instead 
decrease to a level of approximately 4 %. This incomplete clearance can be explained with 
the structural conformation of the Fc part associated with glycan pairing favoring M5:M5 
glycoforms. The mannose receptor can only bind to M5 glycoforms that are large enough to 
open the Fc part like the M5:M5 glycoform and provide access for the mannose receptor to 
the attached N-glycans. Smaller glycan structures like the M5:G0F glycoform result in a 
closed Fc part structure that prevents the mannose receptor from binding. Thus, a certain 
fraction of M5 containing protein molecules show a similar, slower clearance as the non M5 
or M6 containing glycoforms. The observed disappearing of M6 is contradictory to literature. 
It was reported that after an initial decrease of M6 of about 50 % the levels remain fairly 
constant over time (6, 9). In the present case it is either due to a different M6 removal or 
conversion mechanism in rabbits or simply due to a drop of more than 50 % of initial M6 
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levels below the detection limit of the method. The latter is rather likely due to the low 
abundance of M6 especially after initial decrease. 
Summarizing the innovative approach for glycan PK profiling with its high sensitivity works 
with preclinical samples. The preclinical study results confirm previous findings from 
individual human case studies. Thus effect of N-glycosylation can be detected earlier in 
biopharmaceutical development which allows optimizing N-glycosylation via glyco-
engineering before entering clinical phases. 
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Chapter 6 
 
The influence of glyco-variants on the 
pharmacokinetics of a multiply glycosylated 
therapeutic Fc fusion protein 
 
This chapter is intended for publication 
 
Abstract 
Fc fusion proteins are closely related to monoclonal antibodies and can carry several N-
glycans which possibly influence the pharmacokinetics. The effect of N-glycans on the 
pharmacokinetics of two batches of a Fc fusion protein was investigated in a rabbit study. 
The proteins were recovered from serum using a two-step 96-well format based affinity 
purification. Subsequently the N-glycans were released and analyzed after 2-AA labeling by 
nanoLCMS with site specificity. Individual glycan PK analysis was achieved using stable 
heavy isotope labeled N-glycans as internal standards. High sensitivity and low sample 
consumption enabled the integration of the technology into the preclinical and clinical 
biopharmaceutical development. It could be demonstrated that terminally galactosylated 
glycoforms located at the fusion protein receptor part were cleared faster from circulation 
than the average of all protein variants as determined by conventional ELISA technologies. 
Terminal sialic acids in contrast increased the serum half-life. Fc glycans were constant and 
showed no influence on the pharmacokinetics. These site specific investigations of individual 
N-glycan influence on the PK performed during preclinical development are useful to guide 
biopharmaceutical development with respect to N-glycosylation 
Keywords: Fusion protein, N-glycosylation, pharmacokinetics, nanoLCMS, stable heavy 
isotope standard 
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6.1 Introduction 
Fc fusion proteins are closely related to mAbs, both having an IgG related Fc part resulting in 
similar effector functions. The target binding part of Fc fusion proteins is usually a receptor or 
receptor domain that binds with high specificity and selectivity to their ligand. In contrast to 
IgG glycosylation fusion proteins often carry several N-glycosylation sites in the non-IgG 
receptor part (1–4). N-glycosylation has been demonstrated to influence structure and 
function of IgGs and distinct N-glycans were connected with increased clearance of mAbs in 
several studies (5–10). Carbohydrate-specific receptors were thought to selectively bind N-
glycans of glycoproteins which resulted in a faster removal of these glycovariants from 
circulation by endocytosis (11, 12). An influence from N-glycosylation on fusion protein PK 
has been reported in a few studies. Comparing the PK parameters of different batches of 
lenercept, an Fc fusion protein with two extracellular domains of a TNF-α receptor, showed 
that proteins carrying terminal N-acetylglucosamine residues were cleared at an increased 
rate. It was hypothesized that the mannose receptor is responsible for the observed 
clearance which was earlier described to bind N-acetylglucosamine residues (3, 13). Jones 
et al. came to a similar conclusion, again using lenercept and also stated that terminal 
GlcNAc residues may have a higher clearance rate. In contrast terminal sialic acids and 
terminal galactosylation had no impact on the PK (2). Kogelberg et al. studied an antibody-
enzyme fusion protein produced in P. Pastoris with a high portion of high mannose N-glycans, 
mainly M8 and M9. This fusion protein was substantially cleared via the mannose receptor as 
well (14). A glyco-engineered version of the same expression system P. Pastoris was used 
to produce fusion proteins and mAbs which were compared to the same biopharmaceuticals 
produced in CHO cells in transgenic mice studies. It was found that sialic acid content of the 
fusion proteins modulated the pharmacokinetics (15, 16). All published studies analyzed the 
N-glycans as a mixture of Fc and receptor N-glycans although there might be substantial 
structural variations at the N-glycosylation sites resulting in different accessibility of the 
glycans to receptors. It has been reported several times that Fc N-glycans of a certain size, 
e.g. bi-antennary complex type with terminal galactosylation are buried and protected from 
receptor binding (17, 18). In comparison N-glycans located at the non IgG domain might be 
more exposed on the protein surface and accessible for receptors. It is therefore of great 
interest to analyze the influence of Fc fusion protein N-glycans on the PK with site specificity. 
This will lead to a more comprehensive structure-function relationship of N-glycans and the 
fate of therapeutic fusion proteins in circulation. 
To enable analysis of the PK of differently glycosylated protein species including 
differentiation of the glyco-structures attached to the Fc and the receptor part, a previously 
developed affinity purification approach (Chapter 4) was optimized. In this study a high-
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 6 
121 
 
throughput sample preparation procedure encompassing two affinity purification steps using 
Protein G columns and immobilized antigen columns with subsequent N-glycan processing 
and nanoLCMS analysis is presented. This procedure enables investigation of the Fc part 
and the non IgG receptor part located N-glycans individually. The work-flow is completely 
based on a 96-well format. Analysis of 2-AA labeled N-glycans is performed with a highly 
sensitive nanoLCMS approach using reversed phase chromatography which was previously 
shown to be robust and sensitive (19) (and Chapter 3). Quantification is achieved using 
heavy isotopes 2-AA glycan label (20). (20). The use of an internal stable heavy isotope 
standard compensates variations in the sample preparation and nanoLCMS analysis 
resulting in more precise results. Together with the small scale sample preparation N-glycan 
PK data is obtained from 50µl serum samples from a study comparing two different batches 
of the Fc fusion protein performed s.c. in rabbits. 
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6.2 Materials and Methods 
6.2.1 Materials 
2-Aminobenzoic acid, ethanolamine, formic acid, picoline borane, DMSO and 13C 
aminobenzoic acid were from Sigma (Munich, Germany). PNGaseF was from Roche 
(Penzberg, Germany). Acetic acid and acetonitrile were from Merck (Darmstadt, Germany). 
Protein G sepharose, NHS activated sepharose, Sephadex® G-10 96-well plates and 96-well 
deep well plates were from GE Healthcare (Munich, Germany). Multicreen THS HV filter 
plates were from Milipore. Fabricator® (IdeS) was Genovis (Lund, Sweden). 96-well plates 
were from Nunc/Thermo Scientific (Munich, Germany). AcroPrep™ Advance Omega™ 10K 
96-well filter plates were from Pall (Dreieich, Germany). Pre-clinical rabbit serum samples 
were obtained from pre-clinical development/bioanalytics at Sandoz. 
6.2.2 Methods 
6.2.2.1 Fc containing fusion protein 
The Fc fusion protein consisted of two chains linked together by disulfide bonds in the Fc 
region. Each chain was composed of a ligand binding receptor domain fused to the Fc part 
containing a CH2 and a CH3 domain. Each chain carried three N-glycosylation sites, two at 
the receptor part and one at the CH2 domain of the Fc part making a total of six N-glycans 
per molecule. 
6.2.2.2 Preclinical rabbit study 
The preclinical study was performed in Himalayan rabbits. Following single subcutaneous 
administration of 8 mg kg-1 b.w. of two different batches of a fusion protein (FP1 or FP2) 
blood samples (~600 µl) were drawn over a period of time including one pre-dose blood 
sample. Detailed sampling is listed in Table 1. Concentration of FP1 and FP2 in serum was 
determined by ELISA. From remaining serum 2 x 50 µl aliquots were used for glycan PK 
profiling. The first aliquot was analyzed and the second aliquot served as back-up. 
Table 1: Sampling schedule of the pre-clinical study of FP1 and FP2. Prior to the administration a pre-
dose sample was taken from each rabbit. 
Day 1 1 1 1 2 2 2 3 4 6 8 
Hours 
[post-dose] 
0 
(pre-dose) 
2 6 12 18 24 32 48 72 120 168 
 
 
 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 6 
123 
 
6.2.2.3 Preparation of 13C 2-AA labeled glycan standard 
N-glycans of desalted fusion protein (1 mg of a 50/50 mixture of FP1 and FP2) were released 
with use of PNGaseF overnight (17 h) at 37°C. The N-glycans were separated from the 
proteins by use Amicon 30K filter devices and were brought to dryness by use of a speedvac. 
Picoline borane and [13C] 2-AA were dissolved in 70:30 (% v/v) DMSO-acetic acid to furnish 
concentrations of 63 and 50 mg mL-1, respectively. Labeling solution (15 µL) and deionized 
H2O (10 µL) were added to 59 nmol enzymatically released and dried glycans. The Labeling 
reaction was performed at 37°C for 17 h. 
Excess label was removed by gel filtration on G-10 columns. Columns were conditioned with 
10 ml H2O. Samples were diluted to 100 µl with deionized H2O then applied to the column. 
After rinsing the column with 700 µl H2O the purified fluorescence labeled N-glycans were 
eluted with 600 µl H2O. Purified [13C] 2-AA labeled N-glycans were aliquoted and stored at -
20°C until use. 
6.2.2.4 Preparation of 96-well plate affinity columns with immobilized Protein G 
Protein G sepharose slurry (200 µL) was added to each well of the 96-well filter plate. Protein 
G sepharose was stored in 20% ethanol which had to be removed before affinity purification. 
Columns were therefore equilibrated with PBS (150 µL) for four times. Liquid was removed 
by centrifugation. 
6.2.2.5 Preparation of 96-well plate affinity columns with immobilized antigen 
Recombinant human produced antigen was reconstituted according to the manufacturer 
instructions. Antigen was dissolved in H2O (1 mg/mL) and reconstituted for 2 hours at room 
temperature. The membranes of a 96 well filter plate were wetted with 1mM HCl (100 µL) 
before addition of 200 µL NHS activated sepharose-isopropanol slurry per well. Isopropanol 
was removed by centrifugation and the columns were washed with 1 mM HCl (150 µL) for 
four times. Antigen solution (100 µL) was centrifuged into the columns and coupling reaction 
took place for 2 hours at ambient temperature. Affinity columns were washed and remaining 
NHS groups were inactivated with use of ethanolamine buffer (4x 150 µL). Finally columns 
were equilibrated with PBS. 
6.2.2.6 Affinity purification of a fusion protein and glycan release 
Serum samples (50 µL) were added onto the equilibrated Protein G column and centrifuged 
through the column. The column was subsequently washed with PBS (150 µL) for six times 
by centrifugation. Bound IgGs were eluted with three times 100 µL elution buffer (0.1 M 
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glycine pH 2.7). Eluat was immediately neutralized with 1 M Tris HCl pH 8.0. The eluat 
contained the target protein as well as other IgGs from serum. 
The eluat containing the target protein as well as other IgGs from serum is immediately 
neutralized with 1 M Tris HCl pH 8.0. Eluat was centrifuged through the affinity columns with 
immobilized antigen and the columns were washed six times with PBS (150 µL). Fabricator 
solution (100 µl; 1U/µl) was centrifuged into the columns to release the glycosylated Fc part 
of the fusion protein. Reaction was performed at 37°C for 30 minutes. Released Fc parts 
were eluted with PBS. PNGaseF with 13C-2-AA labeled N-glycan standards was added to the 
eluted Fc parts as well as onto the column with the antigen bound part. Digests were 
incubated for 17 hours at 37°C. The N-glycans released from the antigen bound protein part 
were eluted with PBS (2x 150 µl). Remaining proteins were removed by ultrafiltration using 
96-well plates with 10K cut-off membranes. Released N-glycans with glycan standard were 
dried by vacuum centrifugation 
6.2.2.7 N-glycan labeling  
Dried sample N-glycans and 13C 2-AA labeled glycan standard were dissolved in H2O (10 µL) 
and 2-AA labeling solution (15 µL; 100mg/mL picoline borane, 50 mg/mL 2-AA in a 7:3 
mixture of DMSO and acetic acid) was added. Labeling reaction took place for 17 hours at 
37°C. 
6.2.2.8 Gel filtration 
96-well plate Sephadex G-10 columns were equilibrated with 800µL H2O. Labeled samples 
were filled up to 100 µL with H2O and applied to the gel filtration columns. 2-AA and 13C 2-
AA labeled N-glycans were eluted with H2O (150 µL). Finally samples were brought to 
dryness by vacuum centrifugation and dissolved in 20 µL H2O for nanoLC-MS analysis. 
6.2.2.9 NanoLC of labeled N-glycans 
NanoLC (Thermo/Dionex Ultimate 3000) was set-up in “preconcentration” mode according to 
the manufacturer manual with a preconcentration column (3µm particles, 75µm x 2cm) and 
an analytical column (2µm particles, 75µm x 25cm). The column compartment was held at 
40°C. The mobile phase of the nano pump consisted of 0.5% formic acid in H2O (component 
A) and 0.5% formic acid in 50% ACN (component B). Mobile phase of the capillary pump 
consisted of 0.5% formic acid and 1% ACN in H2O (component C). The analytical column 
was equilibrated with 2% component B at a flow rate of 300 nl/min. The preconcentration 
column was equilibrated with 100% component C. With a user defined injection routine 8 µl 
sample were stacked between loading solution (0.1% formic acid, 1% ACN in ultrapure H2O) 
in a 20µl sample loop. The sample loop was switched for 2 minutes in-line of the capillary 
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pump flow to allow optimal trapping. Prior to the next injection sample the loop was washed 
with loading solution. After trapping the pre-concentration column was switched into the nano 
pump flow and component B was raised to 30% over 60 minutes, then to 95% over 5 
minutes. After holding at 95% component B for 5 minutes the column was finally re-
equilibrated at 2% component B for 15 minutes. The column outlet was connected to a UV 
detector with a 3 nl flow-cell. 
6.2.2.10 Mass Spectrometry 
The outlet of the nanoLC was directly coupled to an ion trap ESI-MS (Bruker AmaZon) 
equipped with an on-line nano source (Bruker CaptiveSpray®). The ion trap was operated in 
Enhanced Resolution Mode with a capillary voltage of 1.7 kV. Source temperature was set to 
200°C and a dry gas flow of 3 l/min was used to heat the source. 
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6.3 Results and Discussion 
6.3.1 Glycan maps of the two batches tested in the PK study 
N-glycan PK profiling of mAbs is in general less sophisticated than PK profiling of other 
biopharmaceuticals, because mAbs typically carry only one conserved N-glycosylation site 
on each heavy chain at the Fc part. In this case it is not necessary to analyze the N-glycans 
with site specificity. For more complex glycosylated biopharmaceuticals site specificity 
provides additional information that could help understanding the mechanism of clearance. In 
the present case the Fc part carries one N-glycan per chain and the receptor receptor part 
two additional N-glycosylation sites making a total of six N-glycans per molecule. 
 
Figure 1: Fc fusion protein N-glycans of the two different batches (FP1 and FP2) separated into Fc part 
and receptor part. 
 
For individual analysis of the Fc part and the receptor part N-glycans the two parts had to be 
separated. The Fc fusion protein was therefore immobilized via its interaction partner or 
antigen on a sepharose resin and the Fc part was released enzymatically using the IdeS 
enzyme (Fabricator®). IdeS is an endopeptidase which selectively cleaves IgGs and related 
molecules with high specificity below the hinge region producing a Fab2 and Fc/2 fragments. 
IdeS cleaved the IgG Fc part containing fusion protein into a receptor part which is 
connected by disulfide bridges and able to bind the interaction partner or antigen and two 
Fc/2 fragments. After separation and deglycosylation the generated fragments were 
analyzed individually. The resulting glycan maps of FP1 and FP2 are shown in Figure 1. 
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The two batches had a different N-glycosylation pattern. FP1 showed a more heterogenic 
glycosylation pattern whereas FP2 had higher portions of a lower number of different N-
glycans. Both batches contained high percentages of glycan structures with terminal sialic 
acid at their receptor part. Fc glycosylation was typical for antibodies with a high portion of 
complex bi-antennary N-glycans with core fucosylation; some carried an additional sialic acid. 
The main difference between FP1 and FP2 was based on the terminal groups. FP1 had a 
high percentage of terminal GlcNAc residues. In contrast FP2 had a high degree of terminal 
galactose. The level of sialylation was comparable. The glycan structures are depicted in 
Figure 2. 
 
Figure 2: N-glycan structures found in FP1 and FP2. Blue square stands for N-Acetylglucosamine, green 
circle for mannose, yellow circle for galactose, red triangle for fucose. 
 
6.3.2 ELISA analysis of samples from a preclinical PK study of FP1 and FP2 in 
rabbits 
The preclinical rabbit samples were analyzed via ELISA for overall concentration of FP1 and 
FP2. The ELISA results of the five animals of both arms demonstrated a trend to higher 
concentrations of FP1 as compared to FP2 (Figure 3), but significance could not be 
demonstrated. Both profiles reached their tmax after 18 h. Clearance of FP1 appeared to be 
slightly faster which resulted in congruency at 72 h. This discrepancy of the ELISA profiles 
and the differences in N-glycosylation between the two batches stressed the importance of a 
detailed investigation of a potential relationship between these two aspects. Overall the 
serum half-life was shorter compared to mAbs. This indicated different clearance 
mechanisms and probably a reduced affinity towards the FcRn which is involved in recycling 
of antibodies and the resulting long half-life (21, 22). 
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Figure 3: PK profiles (mean, SD) of FP1 (square) and FP2 (diamond) determined by ELISA; average of five 
animals respectively. 
 
6.3.3 Optimization of affinity purification and N-glycan processing 
Before analyzing Fc fusion protein samples from the preclinical study the glycan PK method 
developed previously for mAbs had to be adapted and optimized (Chapter 5). For individual 
analysis of N-glycans attached to the Fc part and attached to the fusion part a new work-flow, 
depicted in Figure 4, was developed. Affinity purification from serum samples (Figure 4A) 
included a pre-clearing step. Protein G sepharose was used to purify IgGs including fusion 
proteins from serum. After protein G binding and intensive washing, IgGs and fusion proteins 
were eluted using acidic conditions. Unspecifically bound glycoproteins that could falsify the 
analysis remain bound to the protein G column. The precleared serum was neutralized and 
added to an affinity column with immobilized antigen. Serum related IgGs were washed from 
the column and the immobilized fusion protein was digested with IdeS (Fabricator®). The Fc 
part was eluted from the column and the receptor part stayed bound to the antigen. 
In the next step N-glycans were released (Figure 4B). The receptor part N-glycans on 
column and the Fc N-glycans in solution. In this step the stable heavy isotope 2-AA N-
glycans were added. The released N-glycans were labeled with 2-AA separately and 
analyzed by nanoLCMS (Figure 4C). L/H ratios of the sample N-glycan MS intensities (light 
signal; L) to the constant heavy isotope standard N-glycan MS intensities (heavy signal; H) 
plotted against time resulted in glycan PK profiles for individual N-glycans. 
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Figure 4: Work-flow of the glycan PK profiling method for fusion proteins (yellow/orange). A) Fusion 
proteins are recovered from serum. A protein G preclearing step captures IgGs and the fusion protein (2). 
After intense washing IgG and fusion proteins are eluted. Unspecific bound proteins (colored dots) 
remain on the column (3). The fusion protein is captured with its immobilized antigen (4) and the Fc part 
(orange) is eluted (5). B) PNGaseF and glycan standard is added to eluted Fc parts (orange) and 
immobilized receptor parts (yellow). C) Released N-glycans are labeled and analyzed by nanoLCMS. 
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6.3.4 Comparison of N-glycan with ELISA PK profiles 
To enable the comparison between the ELISA PK profiles and the N-glycan analysis data, 
relative ELISA concentration were determined by normalizing average profiles to the 
maximal concentration (cmax). Furthermore, the relative concentrations of the individual N-
glycan profiles were determined by normalizing the average profiles, based on the 
determined L/H ratios, to the maximal L/H ratio. Figure 5 shows the average PK profiles of 
the most abundant N-glycan of the Fc part and the receptor part of both fusion protein lots 
determined by nanoLCMS compared to the appropriate average ELISA profiles. N-glycan 
profiles of FP1 G0F, FP1 SG2F, FP2 G1F and FP2 SG2F showed a similar profile compared 
to the ELISA which was somehow expected as the ELISA represented the average profile of 
all protein variants. The tmax of the ELISA and FP2 SG2F curve was reached 18 h after 
administration. The tmax of FP1 G0F, FP1 SG2F and FP2 G1F was reached one sampling 
time point later after 24 h. Elimination rates were similar, too. These findings confirmed that 
the developed and optimized method worked. 
 
Figure 5: Average glycan PK profiles of the most abundant N-glycans compared to the ELISA profile 
(diamond). A) FP1 Fc part G0F (square). B) FP1 receptor part SG2F (square). C) FP2 Fc part G1F (square). 
D) FP2 receptor part SG2F (square). Average of five animals for each fusion protein. 
 
Detailed glycan maps of the Fc and receptor protein part from FP1 and FP2 are shown in 
Figure 6. The N-glycans of the Fc parts were mostly complex biantennary type N-glycans, 
whereas receptor glycans were acidic N-glycans at high percentage. The glycan maps were 
in good agreement with the glycan maps obtained from the drug product (Figure 1). For the 
FP1 Fc part G0F was the most abundant N-glycan (60%) and G1F the second most 
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abundant N-glycan (30%). All other N-glycans were below 10%. The Fc part of FP2 was 
more heterogeneous glycosylated with G1F (50%) as the most abundant N-glycan followed 
by G2F (25%), G0F (15%) and SG2F (10%). The percentages of all glycans were constant 
over time indicating identical PK profiles of the individual glycans for both Fc fusion protein 
lots. The deviation at 32 h (Figure 6A) was most likely due to variations during the affinity 
purification or nanoLCMS analysis and not a short change of the N-glycosylation pattern. 
Also the variation observed between 6 h and 12 h in the Fc part of FP2 (Figure 6C) was due 
to variation of the method and not a significant change of the N-glycan percentages. 
 
Figure 6: Glycan Maps (mean) of FP1 Fc part (A) and receptor part (B) and glycan maps of FP2 Fc part (C) 
and receptor part (D). 
 
SG2F was the most abundant N-glycan at both receptor parts with approximately 40%. At 
the FP1 receptor part G0F (15%) was the second most abundant N-glycan followed by G1F 
(12%), SG2 (10%), G2F (8%), SG1F (8%) and S2G2 (5%). The FP2 receptor part N-
glycosylation was different with G2F (28%) as the second most abundant N-glycan.  G1F 
and SG2 were present with approximately 10%. Both receptor parts contained several minor 
abundant N-glycans with percentages below 5%. In contrast to the Fc parts the percentages 
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of some receptor part N-glycans changed over time in both lots. For FP1 the portion of G0F 
and G2F decreased whereas the portions of SG2F and SG2 showed a trend towards higher 
portions. For FP2 the major N-glycan SG2F increased slightly whereas N-glycan G2F 
decreased drastically over time. 
Figure 7 shows the N-glycans with terminal galactosylation (G1F and G2F) and the N-glycan 
G0F with a terminal N-acetylglucosamine for Fc and receptor parts. Minor abundant glycans 
G2, G1 and G0 lacking the core fucose had constant portions and are not shown. G2F 
contribution decreased over time for both FP1 and FP2. G1F and G0F decreased slightly in 
case of FP1 but remained constant for FP2. These results indicate that FP1 and FP2 
carrying terminal galactosylated G2F were more rapidly removed from circulation. The 
mechanism behind this clearance could be asialoglycoprotein receptor mediated which is a 
C-type lectin expressed in parenchymal cells of the liver (11, 12). This receptor binds 
selectively to exposed galactose residues and sialic acid α2,6Gal/GlcNAc motifs of 
glycoproteins. Binding initiates endocytosis and degradation of these proteins thereby 
regulating the glycoprotein serum concentration (23). The receptor furthermore exhibits 
decreasing affinity from high to small number of terminal galactosylated antennae. This 
would explain the observations for the slight decrease or constant portion of G1F 
respectively. A similar decrease of G0F as observed for FP1 was reported by Jones et al for 
the Fc fusion protein lenercept which was composed of a IgG1 Fc part fused to the soluble 
TNF-α receptor p55 (2). The selective clearance was explained by binding of the mannose 
receptor to the terminal GlcNAc. The mannose receptor has high affinity to terminal mannose 
residues but is also able to bind terminal GlcNAc of smaller N-glycans (14, 24). The 
difference between FP1 and FP2 for the G1F and G0F N-glycan might be due to different N-
glycosylation pairing on the protein and a different accessibility for receptors to bind. The 
receptor part had two N-glycosylation sites in close proximity that could influence the 
surrounding protein structure depending on the combination of N-glycans. The receptor part 
of FP1 was more heterogeneously glycosylated with a higher portion of bigger acidic N-
glycans (Figure 6B) This might facilitated the decrease of G1F and G0F, when paired with a 
bigger glycan, by the asialoglycoprotein or mannose receptor. In contrast FP2 carried mostly 
SG2F and G2F, the latter with decreasing percentages over time and had different N-
glycosylation pairing. In addition the portion of G0F was significantly lower at the FP2 
receptor part (Figure 7C) compared to FP1 (Figure 7A). Therefore a G1F and G0F decrease 
was not detectable. 
Pharmacokinetic Profiling of Therapeutic Proteins and Variants by Mass Spectrometry 
Fabian Higel Chapter 6 
133 
 
 
Figure 7: N-glycans with terminal galactose residues and terminal N-actetylglucosamine residues located 
at the receptor parts of FP1 (A) and FP2 (C) (mean, SD). Terminal sialylated N-glycans present on FP1 (B) 
and FP2 (D) receptor parts are depicted as well. 
 
Plots for terminal sialic acid containing N-glycans of FP1 and FP2 are shown in Figure 7B 
and C. As described earlier the major N-glycan SG2F had a slight trend to increase over time, 
indicating slower plasma clearance. For FP1 also the SG2 contribution and for FP2 that of 
SG1F increased over time. The other acidic N-glycans had constant percentages. Thus the 
addition of at least one terminal sialic acid to the galactosylated N-glycan structure seemed 
to prevent the protein from selective clearance. The discrepancy between FP1 and FP2 that 
increased over time was again maybe related to the glycosylation site. The observation that 
sialylated glycans increase the serum half-life was already discovered in the 1970s by Morell 
et al. (25). The investigators compared sialylated and de-sialylated thus terminal 
galactosylated glycoproteins. They observed fast clearance of the latter in the liver. However 
in the present study an increased half-life of sialylated N-glycans was not only observed 
compared to terminally galactosylated N-glycans, but also compared to all other N-glycans. 
Consequently there must be another underlying clearance mechanism which discriminates 
between sialic and neutral N-glycans of glycoproteins independent of the asialoglycoprotein 
or mannose receptor. 
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An overview of the contributions of all attached glycans with different terminal groups is given 
in Figure 8. The N-glycans were divided into three different groups: i) sialylated containing 
one or two terminal sialic acids; ii) galactosylated summing up all N-glycans with at least one 
terminal galactose moiety and iii) terminal GlcNAc combining all N-glycans with a terminal N-
acetylglucosamine. N-glycans with two characteristics like SG1F which exhibits a terminal 
sialic acid on one arm and a terminal GlcNAc on the other arm was counted to the sialylation 
group. This is justified by the observations that this N-glycan behaved more like a sialic 
glycan than like a terminal GlcNAc glycan as an increase over time was observed at the FP2 
receptor part (Figure 7D) like for other sialic N-glycans. This was most likely due to shielding 
of the charged terminal sialic acid group. The same rule was applied for other N-glycans, e.g. 
G1F had properties of a terminally galactosylated N-glycan. 
 
Figure 8: Influence of terminal sugar moieties. Percentages of terminal sialylation (diamond), terminal 
galactosylation (square) and terminal N-acetylglucosamine (triangle) are pictured for Fc parts (A: FP1; 
C:FP2) and receptor parts (B: FP1; D: FP2). 
 
The composition of the terminal groups at the Fc parts did not change for FP1 (Figure 8A) 
and FP2 (Figure 8C). The two deviations at 6 h (FP2; Figure 8C) or at 32 h (FP1; Figure 8A) 
were most likely related to the analytical method. In contrast the composition of the terminal 
groups at the receptor part (Figure 8B/D) showed a decreasing contribution of protein 
carrying terminal galactose. This decrease corresponded to an increasing fraction of 
glycosylated protein with terminal sialylation. This indicated that the change in receptor part 
glycan levels and the constant glycan levels at the Fc parts were independent. 
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6.4 Conclusion 
N-glycan PK profiling of Fc fusion proteins without domain specificity has been reported 
several times (2, 3). Since Fc fusion proteins usually carry several N-glycans distributed over 
the molecule the value of these studies is limited. The influence of Fc N-glycans might be 
completely different compared to non-Fc glycans because of the protein structure 
surrounding the glycosylation sites. Therefore a new N-glycan PK profiling approach was 
established that allows the specific and separate analysis of Fc and receptor part N-glycans 
of multiply glycosylated Fc fusion proteins. The work-flow included the recovery of the Fc 
fusion protein from serum samples. In a first affinity step using Protein G chromatography the 
complexity of the serum was drastically reduced. The pre-cleared serum was then applied to 
antigen columns. After washing of the immobilized target protein, enzymatic elution of the Fc 
part and N-glycan processing, the labeled N-glycans of the two protein parts were analyzed 
individually. By incorporation of stable heavy isotope 2-AA labeled glycan standards 
variations during N-glycan processing and nanoLCMS analysis were compensated. 
Two different batches of a Fc fusion protein (FP1 and FP2) were compared in a rabbit study. 
The PK profiles of each N-glycan and the relative distribution of the N-glycans over time were 
determined. The two batches were different glycosylated at the Fc and at the receptor part. 
The Fc parts were IgG typically glycosylated with mostly neutral bi-antennary N-glycans and 
10% acidic N-glycans at FP2. FP1 Fc part contained mostly terminal GlcNAc G0F whereas 
FP2 contained mostly terminal galactosylated G1F and G2F. The receptor part of FP1 was 
heterogeneously glycosylated with acidic N-glycans, terminal GlcNAc and terminal 
galactosylated N-glycans. FP2 showed a high level of acidic N-glycans and a higher level of 
terminal galactosylated N-glycans than FP1. The N-glycan PK profiling results demonstrated 
that fusion protein molecules with terminal galactosylated N-glycans that were located at the 
receptor part were cleared at a faster rate than the average molecule. This clearance was 
most likely a receptor mediated process of the asialoglycprotein receptor. This receptor is 
located in the liver, involved in the uptake and clearance of glycoproteins and known for its 
affinity to terminal galactosylated N-glycans (11, 12). This indicated that the N-glycans 
located at the receptor part located were more exposed at the surface than Fc glycans. This 
better access to galactosylated N-glycans at the receptor part for the asialoglycoprotein 
receptor resulted in selective clearance from circulation. The faster clearance of molecules 
carrying a G0F glyan at the receptor part, clearly observed for FP1, might be mediated by the 
mannose receptor as proposed by Jones et al. (2). However, this was not observed for the 
receptor part of FP2 which contained 3% G0F. Additionally, a prolonged half-life of protein 
molecules carrying sialylated N-glycans was observed but could not be explained with the 
two mentioned clearance routes. 
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Thus N-glycosylation of fusion proteins influences the PK. Fc part N-glycosylation (complex 
bi-antennary) had no influence on PK which is in agreement with previous studies (see 
Chapter 5). Protein molecules carrying terminal galactosylated N-glycans and to some 
extend terminal GlcNac N-glycans at the receptor part were cleared faster. If these glycan 
structures are attached to the Fc part the clearance was not accelerated which points to a 
limited accessibility of N-glycans in the Fc structure. The clearance of galactosylated 
structures was due to asiaglycoprotein receptor mediated binding. The clearance of terminal 
GlcNAc was most likely mediated by the mannose receptor. Terminal sialylation led to an 
increase in serum half-life. The mechanism of increased half-life of sialylated receptor parts 
cannot be explained with known clearance pathways. This study was the first reporting 
detailed site specific N-glycan PK profiling of biopharmaceuticals. It was clearly 
demonstrated that domain specific N-glycan profiling provides very important and detailed 
insights. 
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Chapter 7 
 
Final summary 
The overall aim of this PhD-Thesis was to investigate the influence of N-glycosylation of 
biopharmaceuticals (monoclonal antibodies and fusion proteins) on the pharmacokinetics 
and to establish a structure-function relationship. N-glycosylation is one of the most complex 
post-translational modifications with a possible impact on the structure, function, efficacy and 
safety of therapeutic proteins. The analysis of N-glycosylation is difficult especially if the 
protein of interest must be purified from a complex matrix like serum. The heterogeneity of N-
glycosylation and the numerous possible isoforms further complicate analysis and require 
sensitive and robust methods. The analysis of preclinical or clinical samples poses additional 
challenges with high numbers of sample at varying protein concentrations. 
To overcome these challenges several methods had to be developed. First, analytical 
methods for high sensitivity N-glycan analysis with high resolving power had to be 
established. Furthermore, a high-sensitivity sample preparation approach had to be 
developed to enable analysis of preclinical and clinical samples. The methods were finally 
combined and used to characterize samples obtained from two preclinical studies. 
The first step was to develop a LC-MS method for comprehensive N-glycan characterization 
which is described in chapter 2. Therefore, two fluorescence labels 2-AA and 2-AB are 
evaluated in combination with reversed phase chromatography which is a proven 
chromatography system with a highly MS compatible mobile phase for protein analysis. The 
labeled N-glycans are separated according to their glycan type and fucosylation. The method 
enables the reproducible analysis of sialic and neutral N-glycans. 2-AA as reducing end label 
was demonstrated to be advantageous in comparison with the frequently used 2-AB since 
the retention of 2-AA labeled glycans on the reversed phase is stronger resulting in a higher 
resolving power of the method. In addition MS ionization efficiency in positive ionization 
mode is increased in combination with the acidic mobile phase. Quantitative data of neutral 
2-AA N-glycans obtained by LC-MS were highly comparable to results of RP-HPLC analysis 
of the 2-AA labeled glycans using fluorescence detection. 
The developed on-line LC-MS approach was further improved to achieve a higher sensitivity 
necessary for (pre)clinical samples by decreasing dimensions to nanoLC with on-line 
nanoESI-MS which is described in chapter 3. In comparison with the previously developed 
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LC-MS approach the nanoLC-MS method has an increased resolving power and higher 
sensitivity. Injection of 400 amol of G0F standard N-glycan can still be analyzed with good 
signal to noise ratio and with method linearity over more than three orders of magnitude. Like 
for the LC-MS method neutral and acidic N-glycans can be analyzed by nanoLC-MS in a 
single run. Furthermore it was demonstrated that quantitative MS data of neutral and acidic 
2-AA glycans is highly comparable to UV data. Three possible applications were shown 
exemplarily: First, highly sensitive glycan mapping of recombinant IgGs drug substance, 
second, nanoLC-MS glycan mapping of recombinant Fc fusion protein after protein A affinity 
purification in 96 well plates from cell culture supernatant or harvest broth to support pool 
and clone selection and third, for N-glycan biomarker discovery in serum. 
In chapter 4 the development and qualification of a sample preparation and N-glycan 
processing approach for preclinical and clinical samples is described in detail. The method 
was a 96 well format based affinity purification. This antigen based approach was shown to 
be suitable to recover monoclonal antibodies from preclinical and clinical serum samples and 
can easily be implemented in existing development work-flows. The purification was efficient 
and highly reproducible and enabled the analysis of mAb N-glycans from 50 µl serum. The 
nanoLC-MS analysis in combination with stable heavy isotope internal standards was 
advantageous compared to nanoLC-MS alone (chapter 3) or when using the developed LC-
MS method as described in chapter 2. The method was further qualified with respect to 
linearity, reproducibility and robustness. A study simulating decrease of terminal 
galactosylation of an IgG1 biopharmaceutical proofed the viability of the N-glycan PK 
profiling methodology. 
The developed N-glycan PK profiling method was subsequently used to analyze the glycan 
PK profiles of an IgG1 biopharmaceutical in a preclinical rabbit study (chapter 5). Ten N-
glycans of the mAb with a portion of at least 0.1% and at a minimal concentration of 10 µg/ml 
were successfully analyzed. The glycan composition contained high mannose type, bi-
antennary complex type and hybrid type. Relative ELISA concentration which represents the 
average PK profile of variants/glycoforms present was compared to the relative concentration 
of individual N-glycans obtained from ratios of sample N-glycan to stable heavy isotope 
internal standard N-glycan. It was shown that the PK profiles are highly similar with total 
congruency for most N-glycans with except of high mannose type. High mannose glycans 
M6 and M5 showed different PK profiles compared to ELISA, differences that were also 
observed in glycan maps showing the relative N-glycan composition over time. The relative 
amounts of M6 and M5 decreased over time. M6 totally disappeared and M5 levels dropped 
from initially 10% to approximately 6%. M6 decrease could be explained by mannosidase 
activity in the blood stream. Accordingly M6 is rather converted to M5 than selectively 
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cleared. M5 decrease in contrast can be explained with selective clearance of M5 glycoforms 
through the mannose receptor. The incomplete clearance of M5 in turn might be due to 
favored M5:M5 glycoforms of the investigated IgG1 that are thought to open the Fc part 
making the N-glycans accessible for receptor binding. The results confirmed previously 
published N-glycan PK data in a single human subject by another group and demonstrated 
the usefulness of the developed approach in preclinical development. On the basis of the 
presented data structure-function relationships can be established and the uncertainty of 
individual N-glycan contribution to the PK can be reduced. 
The developed N-glycan PK profiling method was finally adapted to investigate a preclinical 
rabbit study of a fusion protein which is described in chapter 6. The fusion protein consists of 
a receptor part connected to an IgG Fc part. Both domains are glycosylated. Therefore 
affinity purification was extended with an additional purification step using protein G columns 
in 96 well format. The additional step reduced the serum complexity drastically and allowed 
on-column deglycosylation of the immobilized receptor part after enzymatic release and 
elution of the Fc part in the antigen affinity purification step. With this procedure the N-
glycans can be analyzed domain specifically (receptor part and Fc part). In the rabbit study 
two differently glycosylated batches of the fusion protein were compared. Comparison of N-
glycan PK profiles with the respective ELISA profile revealed differences indicating an 
influence of the N-glycans. Glycan maps showed that percentages of terminal galactosylated 
N-glycans decreased over time whereas percentages of terminal sialylated N-glycans 
increased relatively over time. This observation only applied for N-glycans located on the 
receptor part, whereas Fc part N-glycan portions were constant. The decrease of terminal 
galactosylated N-glycans could again be explained with a receptor mediated clearance. The 
asialoglycoprotein receptor expressed in the liver binds selective terminal galactose moieties 
and removes the glycoprotein from circulation by endocytosis. Capping of the terminal 
galactose residues with sialic acids might prevent this clearance. In contrast to Fc part N-
glycans the receptor N-glycans are thought to be exposed and more accessible to receptor 
binding. The two investigated batches of the fusion protein exhibited different galactosylation 
and sialylation levels which might explain the slightly different PK profiles. These findings are 
the first to demonstrate site specific influence on the PK through N-glycans. The results 
clearly show that complex type Fc glycans do not influence PK, but receptor N-glycans of the 
same molecule do. These findings were so far not described in literature. 
In summary, a novel N-glycan PK profiling technology applying MS methods was 
successfully developed. To achieve this a sample preparation workflow had to be optimized 
including isolation of the target protein from the complex matrix, selective release of the N-
glycans and labeling with 2-AA. In addition a (nano)LC-MS based method had to be 
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developed as well. Quantification was achieved using isotopically labeled 2-AA as reference 
standard. The applicability of the developed technology was demonstrated analyzing 
samples of two pre-clinical studies. The results obtained from these studies contribute to the 
understanding of N-glycosylation related influence on the pharmacokinetics of 
biopharmaceuticals.  
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List of abbreviations: 
2-AA   Anthranilic acid or 2-Aminobenzoic acid 
2-AB   2-Aminobenzamide 
ACN   Acetonitrile 
ADCC  Antibody dependent cell-mediated cytotoxicity 
ANTS   8-Aminonaphththalene-1,3,6-trisulfonic acid 
b.w.  body weight 
CE  Capillary electrophoresis 
CDC  Complement-dependent cytotoxicity 
CHO  Chinese hamster ovary 
CID  Collision induced dissociation 
DMSO  Dimethyl sulfoxide 
EIC   Extracted ion chromatogram 
ELISA  Enzyme linked immunosorbent assay 
ER  Endoplasmatic reticulum 
ESI   Electrospray ionization 
Fc  Fragment crystalizable 
FcRn  neonatal Fc receptor 
FLD   Fluorescence detector 
FP  Fusion protein 
GlcNAc N-actetyl-D-glucosamine 
HILIC   Hydrophilic interaction liquid chromatography 
HPAEC-PAD High-Performance Anion-Exchange Chromatography with Pulsed 
  Amperometric Detection 
HPLC   High-performance liquid chromatography 
IgG  Immunoglobulin G 
LC   Liquid chromatography 
LLOQ  Lower Limit of Quantification 
mAb   Monoclonal antibody 
MALDI  Matrix assisted laser desorption ionization 
MS   Mass spectrometry 
NMR  Nuclear magnetic resonance spectroscopy 
PK  Pharmacokinetics 
PNGaseF  Peptide N-Glycosidase F 
PGC   Porous graphitized carbon 
RNase B Ribonuclease B 
RP   Reversed phase 
RPC  Reversed phase chromatography 
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